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ABSTRACT 
FUNCTIONAL PROTEOMIC ANALYSIS OF THE MYOCARDIAL PKCE SUBPROTEOME AND 
PKCE-AKT-eNOS SIGNALING MODULES DURING CARDIOPROTECTION 
Jun Zhang 
September, 2003 
Ischemic heart disease is the leading cause of mortality and morbidity in Western societies. Thus, 
understanding the molecular mechanisms to reduce myocardial ischemia and limit infarction size 
are of great importance. Ample evidence has shown that protein kinase C epsilon (PKCE) play an 
essential role in the genesis of cardioprotection. In particular, our laboratory has shown that 
activation of PKCE in the heart is sufficient to significantly reduce myocardial infarction due to 
coronary artery occlusion. However, the molecular mechanism responsible for PKCE-induced 
cardioprotection remain unclear. Recently, functional proteomic analysis have demonstrated that 
PKCE forms signaling complexes with various of proteins, including structural proteins, signaling 
molecules, stress-activated proteins, transcriptional/translational factors, metabolism-related 
proteins, and PKC-binding domain containing proteins, and the coordination of these molecules 
contributes to cardioprotection. Despite this information which obtained from whole heart Iysates, 
little is known regarding the cellular mechanisms that regulate the assembly of these protein 
complexes and the specific manner in which these molecules interact with each. Therefore, this 
dissertation is focused on the characterization of PKCE subproteome and Signaling modules 
within, as well as their regulation during cardioprotection. PKCE-Akt-eNOS signaling module is 
chosen as my research paradigm because the individual molecule PKCE, Akt and eNOS has 
v 
been implicated in the prevention of cell death. In addition, both eNOS and Akt were found to 
exist in the PKC£ complex in our initial studies, suggesting that functional coupling among these 
molecules may be a heretofore unrecognized protective signaling mechanism. Our data 
demonstrate that the cardiac PKC£ signaling subproteome is comprised of various sizes of 
protein complexes, and the formation of these complexes and modules is regulated by the 
subcellular localization and extracellular stimulus. During cardioprotection, activation of PKC£ 
enhances the PKC£-Akt-eNOS module formation, and thus contributes to the regulation of nitric 
oxide production and hence the manifestation of the cardioprotective phenotype. In conclusion, 
the present research successfully characterizes the myocardial PKC£ subproteome and PKC£-
Akt-eNOS signaling modules, which serves as an important step towards our complete 
understanding of the signaling mechanisms underlying PKC£-mediated cardioprotection and 
ultimately aids in the development of pharmacological agents to protect the heart. 
Vl 
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CHAPTER I 
General Introduction And Overview 
Proteome, subproteome, and module 
Upon completion of the human genome project, we have entered the era of proteomics. 
Proteomics is the study of the proteome, which was first defined in 1995 as all proteins expressed 
by the genome of an organism or tissue (175). Despite the power of genomic technologies, and 
the information derived from a sequenced genome, it is clear that proteins are ultimate functional 
units within cells, and the coordination of them determines the biological phenotype. Therefore, 
mapping the human proteome will bridge the gap between genomics and systems physiology, 
and provide tremendous information for diagnostic and therapeutic applications. 
The goal of proteomics is to globally map protein expression profiles and protein-protein 
interaction profiles within the whole organism (133, 134). However, the generation of proteome 
map faces great challenges. First, one gene does not encode a single protein. Indeed, the 
number of proteins in the entire human body is expected to be many times higher than that of 
genes (81, 96). Second, concomitant co- and post-translational modification events, such as 
phosphorylation, glycosylation, sulphonation, palmitoylation, hydroxylation, acetylation and 
myristolation et aI., which play critical roles in cellular function, can further increase the complexity 
of protein products from a single reading frame. For example, it is estimated that 30% of all 
cellular proteins contain covalently bound phosphate (94), and phosphorylation events control the 
majority of the Signal transduction pathways in eukaryotic cells. Third, in contrast to the static 
genome, the proteome is a dynamic entity that is constantly being modulated by biological and 
environmental stimuli (74, 86). Fourth, the architecture of a proteome is both cell and organ 
specific. Finally, although significant advances have been made in the development of practical 
proteomic techniques, more high-throughput platforms need to be evolved to enhance the power 
of current approaches (95). Taken together, mapping the entire proteome is a long-term project 
due to its enormity and complexity. 
Instead of characterizing every protein within the cell, the goal of functional proteomic 
analysis is to analyze the spatial and temporal properties of the specific sets of proteins, called 
subproteomes in a cell, tissue, or organism, which are related to the particular biological functions 
(73, 170, 173). Compared with the tranditional proteomic analysis, functional proteomic studies 
are more feasible and advantageous. Proteins are not separate islands that perform their 
functions entirely by themselves. Instead, mounting evidence supports the concept that a protein 
may assembly of multi-protein complexes with other proteins to serve as a means to accomplish 
complicated tasks of cellular function (3). Characterization of the specific subproteome provides 
information about the components of the protein complex, and its dynamic changes, including 
protein expression, modification, and subcellular localization, in response to different conditions. 
So far, several studies (6, 22, 66, 71, 87, 98, 99, 101, 113, 132, 155) have undertaken the 
characterization of different subproteomes, including those defined by the MAPK cascade, the 
NMDA receptor complexes, nucleoporin complexes, and the PDGF receptor signaling system. 
Within the subproteome, two or more proteins are associated to form a basic functional unit of 
signal transduction, called a module, which conducts different tasks at various subcellular 
compartments. The formation of many distinct modules contributes to the establishment specific 
biological phenotype (170, 172). 
A technical platform has been developed in our lab for comprehensive analysis of 
functional subproteomes (Figure 1) (135, 170, 171). In order to characterize proteins that 
associate with a protein of interest, isolation and purification of protein complexes is the first step. 
After subcellular fractionation which is an effective way to reduce the complexity and enrich the 
low-abundance proteins, immunoprecipitation and recombinant protein-based affinity pull down 
assays are commonly used to isolate protein complexes. Protein complexes are then separated 
by one- or two-dimensional electrophoresis, or liquid chromatography, followed by mass 
spectrometry or Western blotting to identify components within each complex. Several techniques 
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aid the further study of identification proteins, such as confocal microscopy to confirm the 
subcellular localization, biochemical in vitro assay to test the protein-protein interaction, and 
protein assays to detect the protein expression profiles within the subproteome. Finally, 
determination of the functional role of individual protein within the subproteome can link proteomic 
data to a physiological phenotype. This step can be conducted by using cell culture or transgenic 
animal models, or treatment of activators or inhibitors to test the biological significance of the 
protein change in response to the changed environmental conditions. 
Similarly, the cardiac proteome is proposed to compose of multiple integrated functional 
subproteomes, each of which is organized to facilitate a unique function. Moreover, specific 
modules are formed within subproteomes in response to different stimuli (145, 160, 172). Instead 
of attempting to Simultaneously examine all proteins in cardiac cells, we focus our research on 
characterization myocardial subproteomes that are critically involved in the development of 
ischemic injury and cardioprotection, especially the subproteomes of protein kinases associated 
with cardioprotection (136, 142, 172). Three aspects are important to characterize a 
subproteome: the identification of the proteins that compose the subproteome are classified 
according to their biological functions; the molecular architecture of the subproteome, the manner 
in which the subproteome is altered in different subcellular locations; and the dynamic modulation 
of the subproteome that underlies the development of a specific phenotype. Delineation of 
multiple subproteomes based on their respective biological functions and contributions to 
phenotypes will eventually lead to full characterization of cardiac proteome. 
The goal of this dissertation was to contribute to this understanding of cell signaling in 
two fundamental regards. First, as detailed in Chapter III, we wanted to examine the role of 
subcellular-dependent regulation of signal transduction by testing the basic hypothesis that the 
cell recruits different proteins to regions of the cell to perform specific tasks, and that multiprotein 
complexes are involved in this phenomenon. Second, as reported in Chapter IV, we targeted 
investigation of a specific signaling module within the cardiomyocyte to test a separate but 
equally central hypothesis, namely, that the cell organizes multiple molecules into signal 
transduction units (or modules) that are mobilized to accomplish signaling events and to regulate 
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phenotype. In this regard, the present dissertation advances our understanding of cell signaling in 
general on two critical levels that are interrelated to the common theme of PKCE-mediated 
card ioprotection. 
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Ischemic injury and cardioprot.~ction 
Ischemic heart disease is the leading cause of mortality and morbidity in Western societies (25). 
Thus, mechanisms to reduce myocardial ischemia and to prevent myocytes death are of great 
importance to improve patient survival. Due to the limited ability of the heart to regenerate 
cardiomyocytes, myocardial cell death is the most deleterious event in the heart. In the past, 
numerous attempts had been undertaken to prevent myocardial cell death and limit the infarct 
size after a coronary artery occlusion. An endogenous protect live defense mechanism termed 
ischemic preconditioning (PC) was discovered in 1986 (128), and exerts a very powerful anti-
infarct effect. Ischemic PC is a phenomenon whereby brief ischemic episodes activate an innate 
protective system in the heart to render the heart powerfully resistance to subsequent prolonged 
lethal ischemic insults. Over the past 16 years, a tremendous evidence has demonstrated that 
this protective phenomenon exists in virtually all mammalian nnodels(11, 23). It is hoped that 
elucidation of the intracellular signaling mechanisms underlying the myocardial preconditioning 
may lead to delivery of effective therapeutic agents capable of reducing the myocardial infarction. 
Importantly, cardioprotection can also be engendered by the administration of pharmacological 
agents such as nitric oxide (NO) donors in lieu of ischemia (140, 179, 181). NO donor-induced 
cardioprotection may have potential clinical applications. 
Mounting evidence has demonstrated that protein kinase C epsilon plays a critical role in 
the genesis of cardioprotecion (49, 75, 117, 143, 186). In particular, cardiac-specific activation of 
PKCc: affords an infarct-sparing effect similar in efficacy to that induced by ischemic and 
pharmacological PC. However, the molecular and cellular mechanisms underling PKCE-induced 
cardioprotection are poorly understood. 
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Protein kinase C epsilon (PKCE) 
The protein kinase C (PKC) family of serine-threonine kinases is composed of 12 different 
isoforms that are divided into three subgroups based on their regulation. The classical or 
conventional PKCs (cPKCs) include the a, PI, PII, y isoforms, and are regulated by Ca2+, 
diacylglycerol (DAG), and phosphatidylserine (PS). The novel PKCs (nPKCs), which include the 
E, 8, Tj, and e isoforms, are regulated by DAG and PS; but are insensitive to Ca2+. The atypical 
PKCs (aPKCs) include the 1;;, t, and Ie isoforms and are regulated by PS alone. The /l isoform of 
PKC (also known as PKD), which is sensitive to both DAG and PS, has been placed into a 
separate class because of its unique structural characteristics (12'9) (Figure 2). 
Molecular structure of PKCc : Protein kinase C E (PKCE) was first cloned in 1987 and 
defined as a novel PKC isoform. Akin to other PKCs isoforms, PKCE consists of two primary 
functional domains: an amino-terminal regulatory domain and a carboxyl-terminal catalytic 
domain (129) (Figure 2). Within the regulatory domain, there are two C1 regions and one C2 
region. The C1 region contains C1A and C1B which form the DAG/phorbol esters binding site via 
the cysteine-rich Zn2+ finger motif. An autoinhibitory pseudosubstrate sequence precedes the C1 
domain which can autoinhibit PKCf: to form an inactive closed conformation by occupying the 
catalytic substrate-binding cavity. Unlike cPKCs, the C2 region of PKCE lacks the specific 
aspartate residues which contribute to the Ca2+ binding. Therefore, activation of PKCf: is not 
dependent upon the concentration of Ca2+ ions. The catalytic domain has an ATP-binding site 
(C3) and a substrate-binding site (C4), both of which are essential for kinase activity. The hinge 
region between C2 and C3 domain can be easily cleaved to release the carboxyl terminal 
constitutively active enzyme (kinase domain) when PKCE is membrane-bound (Figure 3). 
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Regulation of PKC/:: There are at least three conserved phosphorylation sites within 
PKCE that are necessary for the maturation of PKCE and its ability to respond to second 
messengers. The first, rate-limiting step is the phosphorylation of Thr566 in the activation loop 
(kinase core). Phosphoinositide-dependent kinase-1 (PDK-1) may be involved in this 
phosphorylation event that leads to the exposure of C-terminus of PKC to the following two 
phosphorylation modifications via intracellular autophosphorylation or catalysis by other kinases 
(33, 161). These two phosphorylation sites are Thr710 at the turn motif (164), and Ser729 in 
hydrophobic site in C-terminus. Phosphorylation of these three sites results in conformational 
changes of PKCE that not only lock PKCE into a more thermally stable, protease- and 
phosphatase-resistant stage, but also free the substrate-bindin~l cavity for pseudosubstrate to 
form the closed conformation (Figure 3). 
Mature but inactive PKCE localizes in the cytosolic fraction where it is maintained in the 
autoinhibited closed conformation. PKCE can be activated by several different second 
messengers, including, DAG, PIP3 (phosphatidylinositol 3,4,5-triphosphate), and fatty acids that 
are produced by physiological stimuli such as PDGF (platelet-derived growth factor) and 
bradykinin (72, 127). After stimulation, PKCE binds to membrane-associated DAG via its C1 
domain. This stimulates the translocation of PKCE from cytosolic fractions to membrane fractions 
where C2 region can interact with membrane phosphatidyl serine (PS) (129). This tethering of 
both C1 and C2 regions to membrane lipids provide the energy to release the pseudosubstrate 
motif from the catalytic domain and open the enzyme's conformation, resulting in maximal PKCE 
activation. 
Subcellular distribution of PKC/:: The subcellular distribution behavior of PKCE depends 
on (i) which second messenger is bound to C1 domain and (ii) which intracellular compartment 
the PKCE-specific binding partner, called RACK2 (also known as W-COP), is localized. This latter 
molecule binds the C2 (-like) domain of PKCE and modulates its activity. Therefore, both the C1 
domain and C2 domain of PKCE function as subcellular localization signals (112). The spatial-
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and temporal- regulation of PKCE subcellular localization may provide the explanation for its 
substrate specificity in the signaling transduction. 
Function of PKC£ in non-cardiac cells: PKCE is expressed in many tissues and cells, with 
particular abundance in neuronal, hormonal, and immune cells. PKCE has been reported to play 
essential roles in a variety of cellular signaling processes (2), including proliferation, 
differentiation, gene expression, muscle contraction, mechanical force adaptation, metabolism, 
transport, exocytosis, endocytosis, and inflammation. PKCE deficient mice show macrophage 
dysfunction due to decreased activation of the transcription factor NF-KB, resulting in increased 
mortality after bacterial infection, and indicating the important protective role of PKCE in the 
immune system (32). In the neuronal system, PKCE induces neurite outgrowth during neuronal 
differentiation through its interaction with actin filaments (106). PKCE has also been implicated in 
the regulation of nOCiceptor function that partiCipates in the perception of pain (46). Moreover, 
PKCE could promote cell survival and prevent apoptosis through suppression of the exitotoxic 
glutamate receptor in neuronal PC12 cells (167), and through dysregulation of the mitochondrial 
caspase pathway in lung cancer cells (46). 
PKC£ and cardioprotection: In cardiac cells, multiple investigators have found that 
activation and translocation of PKCE serves as a central signaling event in the development of 
cardiac protection (75, 117, 140-142). In the past several years, studies from our laboratory (140-
142) have shown that cardiac-specific overexpression of PKCE in transgenic mice hearts can 
mimic protection against myocardial infarction by ischemic preconditioning (Figure 4). Studies 
based on the cardio-specific transgenic expression of the PKCE-selective translocation inhibitor 
(epsilonV1) or activator (\lfepsilon RACK) peptides from other groups also clearly show the 
importance of PKCE in the cardiac protection against ischemic damage as well as during normal 
postnatal myocardial development (50). Furthermore, moderate ethanol consumption exerts 
beneficial cardioprotective effects via mechanisms that involve PKCE activation (188). 
Although PKCE has an established role in the genesis of cardioprotection, the molecular 
and cellular mechanisms responsible for PKCE-mediated cardiac protection remain unclear. 
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Mounting evidence suggests that PKC-dependent protection involves a battery of kinases 
(tyrosine kinases, Akt, PI3-K, mitogen-activated protein kinase (MAPKs)) (145, 146, 166), stress-
activated proteins (heat shock proteins (HSPs), nitric oxide synthases (NOSs), ion channels, and 
pro-survival transcription factors (NF-KB, HIF-1 ex). Recently, using functional proteomic 
approaches, our laboratory has demonstrated that PKCE forms signaling complexes with multiple 
proteins and that the coordinated action of these molecules confers protection against ischemic 
injury (12, 20, 21, 130). In other words, there is a cardiac signaling network centered around 
PKCE that is critical for cardioprotection. 
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AKT I Protein Kinase B 
Akt, also called protein kinase B (PKB), is a serine/threonine kinase, which was first discovered in 
1991 by two independent research groups. Akt was initially characterized as the human cellular 
homologue of the viral oncogene v-akt from the transforming retrovirus AKT8 (19, 38, 100). To 
date, three major isoforms of Akt/PKB have been identified, encoded by three distinct gene loci, 
termed Akt1/u, Akt2/P, and Akt3/y. All three isoforms share a high degree of homology at the 
amino acid level (42, 103). Akt2 and Akt3 are approximate 82% identical with the Akt1 isoform. 
Akt3 lacks 23 amino acids at the C-terminal compared with others (110) (Figure 5). All three 
isoforms are ubiquitously expressed in mammals, although levels of expression vary among 
tissues. Akt1 is the predominant isoform in most tissues, such as brain, thymus, heart and lung 
(19, 38, 100). Akt2 is primarily expressed in the insulin-responsive tissues, such as skeletal 
muscle, heart, liver and kidney (7). Expression of Akt3 is more restricted, appearing high in the 
brain and testes, and lower in heart, spleen, lung and skeletal muscle. All tissues contain at least 
one form of Akt. 
Molecular structure of AktlPKB: Examination of the amino acid sequence of AktlPKB 
revealed that all three isoforms contain a highly conserved structure. The N-terminal 100 amino 
acids posses a pleckstrin homology (PH) domain that mediates lipid-protein or/and protein-protein 
interactions. A short glycine-rich region links the PH domain to the catalytic domain. The central 
kinase catalytic domain has a conserved phosphorylation site Thr308 (Akt2 Thr309, Akt3 Thr302) 
within the activation loop. In C-terminal regulatory domain there is another conserved 
phosphorylation site Ser473 (Akt2 Ser474, Akt3 Ser472) (Figure 5). 
Regulation of AktlPKB: In the inactive form of Akt, the PH domain serves as an inhibitory 
structure that sterically blocks the catalytic site (similar to the antoinhibition of PKCE). Activation of 
Akt is initiated by the binding of PIP3 to the~ PH domain of this enzyme. This action not only 
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releases autoinhibition through conformational changes that unmask the active site, but also 
recruits Akt to the plasma membrane where it can be further phosphorylated and fully activated. 
So far, phosphorylation of Thr308 in the kinase activation loop and Ser473 in the C-terminal 
hydrophobic region are the two most important posttranslational modifications. Mutation of 
Thr308 to nonphosphorylatable alanine abolishes Akt 's activation, indicating that phosphorylation 
of Th308 is essential for activation of Akt. In contrast, mutation of Ser473 only partially inhibits Akt 
activation, suggesting that Ser473 phosphorylation facilitates maximal Akt activation but is not a 
necessary step in Akt-dependent signaling (5, 138, 183). 
Ser124 and Thr450, which are constitutively phosphorylated, were also predicted to be 
prerequisite for Akt responsiveness (18), although, mutation of these residues to alanine has no 
effect on the activity of Akt (7, 165). In addition, a recent report finds that Src family tyrosine 
kinase dependent phosphorylation of two tyrosine residues (Y315, and Y326) may contribute to 
the activation of Akt (35). 
The cellular activation of AktJPKB is dependent upon the interaction with membrane-
bound second messager PIP3 The generation of PIP3 is catalyzed by PI-3K via the 
phosphorylation of phosphoinositides (Ptdlns). Although PIP3 does not activate AktJPKB directly, 
it recruits Akt to the plasma membrane and alters the conformation of Akt to facilitate the 
subsequent phosphorylation modifications. The upstream kinase that phosphorylates Thr308 is a 
67kDa ubiquitously expressed kinase called PDK-1 (5, 162, 163). The role of PDK-1 to activate 
Akt has been supported by studies from embryonic stem cells deficient in PDK-1 (177), 
biochemical inhibition of PDK-1 (13), and by studies employing anti-sense oligonucleotides 
against PDK-1 (59). AktJPKB becomes a substrate for PDK-1 once its PH domain engages PIP3 
on the membrane. Interestingly, as indicated above, PDK-1 is also known to phosphorylate and 
activate PKC, though the mechanisms contributing to the specificity of PDK-1 for PKC, Akt, or 
other substrates, remain poorly defined. 
The upstream kinase for Ser473 phosphorylation is unknown, and is tentatively named 
"PDK-2". Several candidate activities have been proposed, including PKCs (34, 190), an 
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unnamed lipid-raft-associated kinase (84), or simply an autophosphorylation processes following 
the PDK-1 activity (1). 
There are two postulated models for Akt activation. The first mechanism in response to 
PI3K induction and PIP3 production, Akt moves from the cytosol to the plasma membrane, where 
Ser473 phosphorylation occurs through autophosphorylation or by PDK2. This region forms a 
docking site for PDK-1 to phosphorylate Thr308 and hence activate Akt (8). The second 
mechanism is that cytosolic Akt and PDK-1 are co-localized, but Akt is inactive due to constraints 
imposed by its PH domain. Growth factors stimulate PI3K, which draw both PDK-1 and Akt to the 
plasma membrane. The PH domain of Akt binds to PIP3, unmasking the activation loop and 
allowing PDK-1 to phosphorylate Thr308. Subsequent elevation of Akt activity promotes 
autophosphorylation of Ser473 or by a third-party enzyme (165). Once Akt is activated, it targets 
specific proteins in the cytoplasm, plasma membrane and and nucleus (Figure 5). 
The consensus motif for Akt phosphorylation is R-x-R-x-x-S/T-F/L (x represents any 
amino acid) (5). So far, several potential Akt substrates have been found, such as glycogen 
synthase kinase-3 (GSK3), IKB-a kinase a (IKKa), Raf, and Bad. Recently, Akt was found to 
regulate the level of nitric oxide (NO) production through direct phosphorylation and activation of 
the endothelial isoform of nitric oxide synthase (eNOS) (44, 63). 
Subcellular distribution of AktlPKB: The subcellular localization of Akt is tightly regulated. 
Two minutes after stimulation by IGF-1, Akt1 is translocated to the plasma membrane in a PH 
domain-dependent manner. Prolon~Jed stimulation induces Akt translocated to the nucleus by an 
unknown mechanism (8), which is PH-domain-independent. 
Function of AktlPKB: Ample evidence shows that Akt is a key player in numerous 
physiological and pathophysiological processes, such as gene transcription, protein synthesis, 
glycogen synthesis, transcription control, cell growth, cell survival and angiogenesis (26, 28, 44, 
62, 63, 67, 69, 121,182). In cardiomyocytes, Akt is activated by gp130 stimulation and has both a 
hypertrophic and an antiapoptotic effect (62, 131). Bell and colleagues reported that 
administration of bradykinin, as an adjunct to reperfusion, limits infarct size in the mouse heart via 
induction of increased activity of Pl3kinase, Akt and eNOS (62). In myocardial gene transfer 
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studies, a constitutively active mutant of Akt reduces infarct size and apoptosis after ischemia-
reperfusion injury (62). Using DNA microarrays, Cook et al (40) reported the cardiac gene 
expression profiles in mice with cardiac-specific overexpression of Akt. Studies from these Akt 
mice also indicate that Akt exerts a dual function in vivo on the myocardium by increasing both 
cardiomyocyte size and contractility (39). They found that chronic Akt activation resulted in the 
differential regulation of at least 40 genes in the heart that may contribute to the effects of Akt on 
cardiomyocyte survival, metabolism, and growth. Interestingly, studies from Zhou's group find that 
moderate alcohol consumption induces sustained cardiac protection is through a PKCE- and Akt-
dependent signaling pathway (188). 
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Endothelial nitric oxide synthase (eNOS) 
Nitric oxide (NO) is a potent messenger molecule that participates in many physiological 
processes such as vascular relaxation, neuronal communication, immunological modulation, and 
host defense (4). NO is produced from oxidizing L-arginine to generate L-citrulline which is 
catalyzed by a family of NO synthases (NOS). There are three distinct isoforms of NOS, referred 
to as endothelial NOS (eNOS, NOS-3), neuronal NOS (nNOS, NOS-1), and inducible NOS 
(iNOS, NOS-2). eNOS and nNOS are Ca2+/calmodulin-dependent enzymes producing NO in 
short bursts and low concentrations (nM), whereas iNOS produces NO in high concentrations 
(f.!M) and is Ca2+ -indenpedent (9). 
Molecular structure of eNOS: eNOS was first identified and isolated from bovine aortic 
endothelial cells (9, 10) in 1991. Since then, it has been found in many cells, such as platelets 
(148), smooth muscle cells (156), cardiac myocytes (14), bone cells, (4) and neurons (27, 45). 
According to the amino acid sequence, the primary structure of eNOS has two functional 
domains: reductase domain and oxygenase domain. The C-terminal reductase domain (10) 
contains NADPH, FAD, FMN, and calmodulin (CaM) binding sites and the N-terminal oxygenase 
domain has binding sites for tetrahydrobiopterin (BH4), heme, and L-arginine (14, 27). In 
particular, the BH4 domain is reported to be critical for eNOS activity (116, 169), as it is involved 
in dimer formation and electron transfer, as well as maintenance of the active site's structural 
integrity (Figure 6). 
The quaternary structure of eNOS inGiudes its dimerization and association with other 
proteins. The eNOS enzyme is the only fully functional in a dimeric form. Dimerization of eNOS 
starts with the binding of heme (108), and the binding of BH4, to stabilize the dimer (102, 116, 
150). The reductase domain transfers electrons from NADPH via the FAD, FMN and CaM co-
factors to the heme in the oxygenase domain. The oxygenase domain catalyzes L-arginine to L-
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citrulline with BH4 binding to O2. CaM bindin!~ increases the rate of electron transfer, by which 
increased intracellular Ca2+ concentration is required for this protein-protein interaction. Hence, 
the Ca2+/CaM-dependence is one of the features of this particular NOS isoform (Figure 6). 
Regulation of eNOS: The regulation of eNOS occurs at three levels: gene transcription, 
co/post-translational modification, and allosteric regulation of the enzyme itself. 
Transcriptional/translational control alters eNOS protein expression levels via regulation 
of the eNOS promoter and altered stability of eNOS mRNA. There are numerous transcription 
factor binding sites on the eNOS promoter, including activator protein (AP)-1, nuclear factor (NF)-
1, nuclear factor-KB (NF-KB). Multiple stimuli can affect the basal expression of eNOS. For 
example, hypoxia leads to the activation of AP-1 and induction of eNOS transcription (53, 89). 
eNOS levels in endothelial cells also can be efficiently regulated by changes in eNOS mRNA 
stability. Hypoxia and cytokines, such as TNF, can downregulate eNOS mRNA levels by reducing 
the half-life of eNOS mRNA from 48 h to as little as 3 h (122, 125, 185, 187). 
There are several phosphorylation modifications within the eNOS protein. Ser1177 
(human) in the reductase domain is the most important one. It is stimulated by the application of 
fluid shear stress (44, 64), estrogen (111), VEGF (107), insulin (58), or bradykinin (16) and results 
in increased NO production. The kinases involved in this process vary with the stimuli and include 
Akt (44, 51), PKA (123), and CaMKl1 (120). In addition, Thr495 within the CaM-binding is 
constitutively phosphorylated in endothelium cells, possibly via PKC, and is associated with 
decreased eNOS activity (43, 85, 120, 123). Moreover, other phosphorylation sites, such as 
Ser114 within the oxygenase domain, are thought to be modified by ERK1/2 (56) and are related 
to the dimerization of eNOS. Ser633 and some tyrosine residues can also be phosphorylated, but 
the functional significance of these post-translational modifications remains to be determined (44, 
56,57). 
Lastly, the molecular chaperone HspS10 serves as an allosteric modulator (65) for eNOS 
activity. Activation of vascular endothelial growth factor, histamine or fluid shear stress in human 
endothelial cell increases the interaction between eNOS and Hsp90, and increases eNOS activity 
by approximate 3-fold. 
15 
Subcellular localization of eNOS: eNOS is largely membrane-associated as a result of N-
terminal myristoylation and palmitoylation modifications (30, 152, 157). When eNOS is located in 
the caveolae, flask-shaped invaginations of the plasma membrane that occupy up to 30% of cell 
surface, it is bound to caveolin. Caveolin is a caveolar resident coat protein that inhibits eNOS 
activity by interfering with Ca
2
+/CaM binding and electron transfer to the heme subunits (9). In 
endothelial cells, eNOS binds to caveolin-1, whereas in cardiac myocytes, eNOS is associated 
with caveolin-3. An increase in intracellular Ca2+ causes the formation of Ca2+/CaM complexes, 
which displaces caveolin resulting in the dissociation of eNOS. At this point, eNOS is now 
activated and remains so until intracellular Ca 2+ levels decrease and the Ca2+/CaM complex can 
no longer compete with caveolin. The specific intracellular compartments to which eNOS 
translocates remain unclear, but many include the nuclear membrane, the endoplasmic reticulum, 
or trans-golgi system (83). 
Function of eNOS: The protective effects of NO generated by eNOS are varied. It 
regulates vascular tone by relaxation of vascular smooth muscle cells (vasodilation) (76). It 
inhibits leukocyte and platelet adhesion and aggregation to endothelium (100) and inhibits 
vascular smooth muscle cell proliferation (156). 
eNOS is the major form of NOS in the heart and it is expressed in endothelial cells and 
cardiac myocytes (14, 105). The protective role of eNOS in the cardiovascular system has been 
widely studied. Myocardial overexpression of eNOS in mice greatly stimulates cardiac NO 
formation and protects the heart against ischemia/reperfusion injury (29). Moreover, gene transfer 
of eNOS to the heart reduces ischemia/reperfusion injury by inhibiting NF-KB activation, adhesion 
molecule expression, and the early infiltration of leukocytes (92). In contrast, eNOS knockout 
mice exhibit increased left ventricular contractdity in response to ~-adrenergic agonists compared 
with wide type mice, demonstrating a negative inotropic effect of eNOS-derived NO (15, 70, 79). 
eNOS is also reported to be involved in the development of ischemic preconditioning. Xuan's 
group report that in conscious rabbit hearts, ischemic PC elicits an immediate activation of Ca
2
+-
dependent NOS (most likely eNOS), indicatin!J that eNOS serves as a trigger on day 1 to initiate 
the development of late PC 24 hours later (18 'I ). 
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PKCE-Akt-eNOS signaling modules 
As detailed above, PKCE plays a critical role in the genesis of cardioprotection against 
myocardial ischemic injury (49, 140-143, 147). Specifically, recent studies in our laboratory 
showed that PKCE forms multimeric signalin!~ complexes with at least 93 proteins, including 
structural proteins, stress-activated proteins, proteins associated with transcription and 
translation, proteins involved in cellular metabolism, and various kinases and phosphatases (52, 
143). Furthermore, the assembly of these multiprotein PKCE complexes is dynamically modulated 
in the PKCE-transgenic mouse hearts, which serves as important evidence for the role of these 
complexes in regulating the cardioprotective phenotype. 
Importantly, among the 93 known protHin partners, Akt and eNOS are of great interest as 
they are well established to independently promote cell survival and prevent cell death in 
response to various forms of stress (16, 42, 60, 63, 104, 124, 182). Taken in the context of the 
foregoing introduction regarding the essential roles of these three molecules in the cardiovascular 
system, the finding that PKCE, Akt and eNOS may be signaling partners in the myocardium was a 
tantalizing piece of evidence suggesting functional coupling of these molecules. As a result, we 
chose to focus our studies to define the specific role of subcellular dependent regulation of the 
PKCE subproteome, and in particular, of PKCE-Akt-eNOS signaling modules within this 
subproteome. 
Accordingly, my research has focused on the identification of PKCE subproteome, and 
the signaling modules within. We hypothesized that PKCE form distinct signaling modules at 
different subcellular compartments with different protein components in the mouse heart, and 
moreover, that the assembly and activation of signaling modules conduct different tasks which 
are essential to the genesis of cardioprotection (Figure 7). In the first part of my research, I 
concentrated on the identification of PKCE subproteome in different subcellular compartments, 
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and the regulation of these protein complexes during cardioprotection. In the second part of my 
study, I focused on the characterization of PKCE-Akt-eNOS signaling modules, which were 
chosen as an example to functionally validate a signaling module in cardioprotection. 
Previous studies in non-cardiac cells have provided evidence for physical and functional 
interaction between PKC, Akt and eNOS. Akt can directly interact and phosphorylate eNOS on 
Ser1177 (63). Doornbos' (48) and Mao's (119) groups reported that Akt can be co-
immunoprecipitated with PKCs or PKCt, and that the PH domain of Akt is implicated as the 
binding site for PKCs to Akt1 (110) and Akt3 (88) in COS-1 cells. Li and colleagues also find that 
PKCu overexpression stimulates Akt activity and suppresses apoptosis induced by interleukin 3 
withdrawals in myeloid progenitor cells (114). In contrast, Wen (176) reported that in A549 and 
HEK293 cells, the phosphatidylinositol 3-kinase/Akt signaling pathway is negatively regulated by 
PKC. Similarly, PMA-induced apoptosis is accompanied by an inhibition of Akt activity (149). 
Moreover, PKC activation inhibited eNOS activity by attenuating eNOS phosphorylation on 
Ser1177 and increasing phosphorylation of Thr495 in cardiovascular endothelial cells (123, 124). 
Despite this information, nothing is known regarding the formation and regulation of 
PKCE-Akt-eNOS signaling modules in myocytes, especially during cardioprotection. Therefore, 
comprehensive investigations need to be implemented to draw a clearer picture of the temporal 
and spatial relationship among PKCE, Akt and eNOS in the regulation of NO production and the 
genesis of cardioprotection. Successful characterization of myocardial PKCE-Akt-eNOS signaling 
modules would serve as a good model for the future research addressing the signaling 
mechanisms underlying PKCE-mediated cardioprotection, and of critical importance in the 
development of pharmacological agents for the treatment of myocardial ischemia and infarction in 
patients. This dissertation provided new information about the molecular architecture of PKCE-
Akt-eNOS signaling module, the subcellular localization of these modules, and the dynamic 
modulation of these modules during the development of the cardioprotective phenotype. 
18 
Figure 1. Functional proteomic platform for isolation and characterization of 
multiprotein complexes. This is a hypothesis-driven research strategy to characterize a 
cellular subproteome responsible for the genesis of a phenotype. Started with subcellular 
fractionation which is an effective way to reduce the complexity and enrich the low-
abundance proteins, immunoprecipitation and recombinant protein-based affinity pull 
down assays are commonly used to isolate and purify protein complexes. Protein 
complexes are then separated by one- or two-dimensional electrophoresis, or liquid 
chromatography, followed by mass spectrometry or Western blotting to identify 
components within each complex. Then, biochemical analyses and phenotype 
assessment are conducted to determine the functional role of individual protein within the 
subproteome and link proteomic data to a physiological phenotype. We use this strategy 
to characterize the PKCE-dependent signaling mechanisms underlying cardioprotection. 
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Figure 2. Molecular structure of protein kinase C epsilon (PKCe). Alike other PKCs, 
PKCE has regulatory domain and kinase domain. Within the regulatory domain, an 
autoinhibitory pseudosubstrate sequence is ahead of C1 motif (dotted red). 2nd 
messenger DAG and phorbol esters bind to C1 domain; whereas, acidic lipids (PS) binds 
to C2 domain. Kinase core has conserved three phosphorylation sites. N is the amino 
terminus. C is the carboxyl terminus. 
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Figure 3. Model of activation of PKCf:. Newly synthesized immature PKCf: need three 
conserved phosphorylation modifications to become maturation which is phosphorylated 
by PDK-1 followed by autophosphorylation. Mature but inactive PKCf: localizes in 
cytosolic fraction. In response to various stimulus, the generation of DAG and PS recruits 
PKCf: to the membrane fraction by engaging the C1 and C2 domains on the membrane. 
This membrane interaction provides the energy to release the pseudosubstrate motif 
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Figure 4. Activation of PKCe reduces myocardial infarction sizes. PKCe transgenic 
mice was generated using a-MHC cardiac-specific promoter. The DNA constructs used 
in the generation of constitutively active PKCe mutant transgenic mice has a point 
mutation at the pseudosubstrate region (A to E at aa159). This mutation would release 
psudosubstrate domain from catalytic site, thus placing PKCe in its open, and therefore 
active confirmation When these mice were subjected to myocardial ischemia, the PKCe 
transgenic mice show significantly decreased myocardial infarction size when 
compared with non-transgenic mice, indicating that active PKCe protect the heart. 
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Figure 5. Molecular structures and activation model of AktlPKB isoforms. Upper 
panel, Akt is also a serine/threonine kinases with three major isoforms. Each isoform 
consists of an N-terminal PH domain, a kinase domain and a C-terminal regulatory 
domain. N-terminal PH domain can mediate lipid-protein or protein-protein interactions. 
Central kinase domain has a conserved phosphorylation site Thr308 which is necessary 
for Akt activation. The hydrophobic C-terminal regulatory domain containing a second 
regulatory phosphorylation site Ser473, which is required for maximal Akt activation. 
Lower panel, inactive Akt mainly resides in the cytosol, and the PH domain is serving as 
an autoinhibitory motif to block kinase domain. (like PS for PKCE). The activation of Akt 
requires the binding of PIP3 to PH domain to unmask the kinase domain, leading to the 
translocation to membrane fraction; Akt activation also requires the phosphorylation 
modifications of Thr308 and Ser473, which is mediated by kinase called PDK1 and 




AktJPKBu PH! rich e"''''':M,?':;Wj,d~in,a~ :do~ain~ . ReJ~~!~~y - ..... , A'.U!. ;~··:Z;Z·H 
AktJPKBP PH f::=:::I"""'~,_"" ,,:iT,,' . ~hr308 ~73 _ •.• ~.!!\ ,0 .. ~ ,iliilt.IIF'1 .. I 
Thr309 Ser474 




/ Translocation Translocation ,/' .. 
---
II PH Hrl!<iiiase·i:!Qii'ia1n.dtt~ 
PP2A 
;""" -:iii+:" :,., .. .. ' • .; -,' .. .... ;&;"* 
!!Sinase' domain. ":' ..- Active Akt '\. 
Translocation 
Inactive Akt 'It ---CNucleau 
00 
N 
Figure 6. Molecular structure of endothelial nitric oxide synthase (eNOS). eNOS is 
Ca2+ -CaM-dependent nitric oxide syntheses, and has two functional domains. C-termianl 
reductase domain and N-terminal oxygenase domain. The myrostoylation (Myr) and 
palmitoylation (Palm) sites on eNOS are shown (important features for eNOS membrane 
localization), and the autoinhibitory loop within the FMN regions of eNOS is also shown. 
eNOS can catalyze arginine to produce nitric oxide. And its activity is highly regulated by 
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Figure 7 Architecture of the cardioprotective PKCe signaling system in 
cardiac myocytes. The hypothetical structure of the PKCe signaling subproteome 
involves various signaling modules located at multiple subcellular compartments, 
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CHAPTER II 
METHODS AND MATERIALS 
All procedures were performed in accordance with the Animal Research Committee guidelines at 
UCLA, which conform with the Guide for the Care and Use of Laboratory Animals, published by 
the National Institutes of Health. 
Antibodies and Chemicals 
Anti- W-adaptin, BMX, caveolin-3, connexin-43, COX-2, desmin, ERK1, HIF-1 a, GM130, Lap2, 
MEK1, eNOS, HSP60, iNOS, NuMA, p38 MAPK, p85 PI-3K, p170 PI-3K, PKCE, Pyk2, Ras, 
RACK1, and villin antibodies were purchased from Pharmingen (San Diego, CA). Anti-AKAP79, 
Akt, ANT1, c-Fos, c-Jun, c-Myc, CREB, Elk, HO-1 HSP27, HSP70, GRP75, hnRNPa2/b1, JNK2, 
lamin-C, Lck, NF-KB (p65), PDK1, Src, STAT1 and 3, Tropinin I and T, vimentin, vinculin, Akt1/2, 
Akt1, Akt2 and Akt3 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA). Anti-aB-crystallin and TCP-a (RACK2) antibodies were purchased from Stressgen 
(Vancouver, BC). Anti-phospho-Akt of Ser308 and Ser 473, anti-phospho-eNOS (Ser1177) 
antibodies and Akt kinase assay kit were from Cell Signaling Technology Inc. (Beverly, MA). Anti-
a-actin and a-actin in antibodies from Sigma-Aldrich (St. Louis, MO). Anti-Na+/K+ ATPase, histone 
H4, PP2A, PP1 antibodies were purchased from Upstate Biotechnology (Lake Placid, NY), anti-
prohibitin-1 antibody from Research Diagnostics (Flanders, NJ), and anti-VDAC1 from 
calbiochem (San Diego, CA). Anti-ribonucleoprotein (RNP) antibody was from NeoMarkers 
(Fremont, CA), anti-glyceraldehydes-3-PDH (GAPDH) antibody was from Biodesign (Saco, 
Maine), and anti-creatine kinase was from abcam (Cambridge, UK). The aldose reductase 
antibody was a generous gift from Dr. Aruni Bhatnagar (University of Louisville). The hnRNPH1 
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antibody and hnRNP K antibody were generous gifts from Dr. Doug Black (Howard Hughes 
Medical Institutes, CA), and Dr. Pradip Raychaudhuri (University of Illinois at Chicago), 
respectively. The Oracle antibody was custom made by BioSource (Camarillo, CA). Cross-linker 
EZ-Link Sulfo-NHS-LC-Biotin and streptavidin:HRP were obtained from Pierce (Rockford, IL). L-
arginine, Bistris, tricine, sucrose, 6-aminocaprioc acid, and other chemicals were purchased from 
Sigma-Aldrich. Recombinant active Akt, unactive Akt, PH domain of Akt, PH domain deleted Akt 
were purchased from Upstate Biotechnology (Lake Placid, NY). Recombinant PKCE and eNOS 
were bought from Biomol (Plymouth meeting, PA) and Calbiochem (La Jolla, CA), respectively. 
PKCe Transgenic Mice 
The cardiac-targeted PKCE transgenic mice used in these studies have been previously 
described (142, 145). This transgenic line exhibits moderate increases in PKCE activity, is 
inherently cardiac protected, and is free from hypertrophy. Transgenic mice and their non-
transgenic littermates were used at 9-12 weeks. 
Subcellular fractionation 
All fractionation procedures were performed at 4°C. Myocardial cytosolic, nuclear, mitochondrial, 
membrane fractions were obtained by differential centrifugation as previously described (12). 
Briefly, mouse hearts were homogenized in buffer containing 250mM sucrose, 10mM Tris-HCI 
(pH?.4), 1 mM EDTA, 1 mM NaN04, and a cocktail of protease inhibitors (Roche, Indianapolis, 
IN). The homogenate was then centrifuged at 1000 x g for 10 min to pellet the nuclear fraction. 
The supernatant was centrifuged at 10,000 x g for 30 min to yield the mitochondrial fraction in the 
pellet (12). The resultant supernatant was subsequently centrifuged at 100,000 x g for 1 hr to 
yield the cytosolic fraction (supernatant) and membrane fraction (pellet). The different membrane 
fractions were then re-suspended in homogenization buffer with 0.5% (v/v) NP-40. Caveolae 
were isolated by differential density centrifugation, as described by Smart et al (159). 
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Immunoprecipitation 
PKCE monoclonal antibodies were covalently cross-linked to protein-AiG beads (Santa Cruz) 
using a commercially available kit (Pierce). Subcellular Iysates (1000/1g) were incubated with the 
immobilized PKCE antibody overnight at 4°C and washed three times with buffer containing 150 
mM NaCI, 20 mM Tris-HCI (pH 7.4), 10 mM EOTA, 1 % (v/v) NP-40, 1 mM NaN04, and a 
protease inhibitor cocktail (Roche). After the final wash, the beads were re-suspended in laemmli 
buffer, boiled for 10 min, and then the supernatants were subjected to SOS-PAGE and 
immunoblotting. If immunoprecipitation was followed by two dimensional (20) electrophoresic 
analysis, after the final wash, the beads were washed with 10% sucrose to remove salt, and the 
protein complexes then dissolved into thiourea buffer (Urea 7M, thiourea 2M, CHAPS 2% (w/v) , 
OTT 65mM, Zwittergent 1 % (v/v), Ampholytes (pH3-10) 0.8% (w/v) , and bromphenol blue 0.01 % 
(w/v) (Genomic Solutions, Ann Arbor, MI). 
Immunoblotting 
Samples were denatured in laemmli buffer, resolved by one-dimensional SOS-PAGE, and 
transferred onto nitrocellulose membranes. After blocking with 5% (w/v) nonfat milk powder, the 
membranes were immunoblotted using the ECl detection system (Amersham, Piscataway, NJ). 
Two-Dimensional Electrophoresis 
Subcellular extracts were loaded onto immobilized pH gradient (IPG) strips (Amersham) and 
subjected to isoelectric focusing in the first dimension as described (142). The IPG strips were re-
equilibrated and subjected to SOS-PAGE (Genomic Solutions) for the second dimension. 
Proteins were then visualized by silver staining. 
Protein Biotinylation 
Following PKCE immunoprecipitation, protein complexes were eluted with low pH elution buffer 
(Pierce) and then dialyzed against PBS overnight at 4°C. To biotinylate the proteins, the dialyzed 
sample was incubated with EZ-Link Sulfo-NHS-lC-Biotin (Pierce) at 4°C for 4 hours. The 
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samples were then subjected to SDS-PAGE, transferred to nitrocellulose membranes, and 
visualized using streptavidin-HRP (Pierce) and the ECl system (Amersham). 
Gel Filtration Chromatography 
Gel filtration chromatography was carried out as described (36) with a few modifications 
Subcellular fractionations which were prepared from 15 hearts in Buffer A containing: 20mM 
HEPES, pH 7.9, 1.5mM MgCI2 , 150mM NaCI, 0.2mM EDTA, 0.5% (v/v) NP-40, and a cocktail of 
protease inhibitors, or total homogenates from two mouse hearts were dialyzed overnight at 4°C 
in Buffer A without NP-40, and clarified prior to chromatography. These samples were then 
loaded onto a pre-calibrated Sephacryl S-400 column (XK 26/70, 26 mm diameter, 70 cm length, 
Amersham) using Buffer A without NP-40 as running buffer. Each 1 ml fraction was collected. 
Proteins were then precipitated with cold acetone, and analyzed by either SDS-PAGE or native 
gel electrophoresis. Thyroglobulin (669kDa), Ferritin (440kDa), catalase (232kDa) and aldolase 
(158kDa) (Pharmacia) were used as molecular standards. 
Native Gel Electrophoresis 
Native gel electrophoresis was carried out as described (153, 154) with minor modifications. In 
particular, deoxycholic acid was used in place of Coomassie blue. Gel filtration fractions were 
precipitated with cold acetone and then solubilized in buffer containing 50mM 6-aminocaproic 
acid, 200mM Bis-Tris, pH 7.0, 20% (v/v) glycerol, and 0.5% (v/v) NP-40 for 1 hour on ice. Then 
samples were mixed with 10x native sample buffer containing 100mM Bis-Tris, pH 7.0, 1M 6-
aminocaproic acid, 35% (v/v) glycerol, and 1.0% (v/v) deoxycholic acid. After clarification, the 
samples were loaded onto 5-13% gradient native gels. Electrophoresis was performed at 100 
Volts with 15mA per gel overnight at 4°C. Thyroglobulin (669kDa), Ferritin (440kDa), and catalase 
(232kDa) (Pharmacia) were used as molecular standards. 
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GST-PKC& Pull-Down 
GST-PKCe affinity pull-down assays were performed as previously reported (142). Briefly, GST-
PKCe recombinant protein was generated using the baculovirus system (Pharmingen). 
Subcellular fractions were incubated with GST-PKCe in binding buffer containing 0.5% (v/v) Triton 
X-100, 20mM Tris-HCI, pH7.4, 150mM NaCI, 1mM EOTA, 1mM EGTA, and a cocktail of protease 
inhibitors (Roche) overnight at 4°C. The beads were washed three times and the proteins eluted 
with glutathione (GSH) elution buffer (Pharmingen). 
Sucrose Gradient Purification 
Proteins eluted from the GST -PKCe pull-down were overlayed on a 10-30% sucrose gradient 
(132). Eighteen consecutive fractions, beginning from the top, were collected. Thyroglobulin 
(669kOa) and catalase (232kOa) were used as molecular standards. Protein fractions were 
precipitated with cold 10% (w/v) TCA and 90% (v/v) acetone, resolved by SOS-PAGE, and 
visualized by silver staining. To identify PKCe signaling complexes, the SOS-PAGE was blotted 
by PKCf antibodies. 
Phosphorylation of Akt or eNOS by PKC& 
Recombinant Akt or eNOS was incubated with PKCe in PKC reaction buffer containing 0.03mg/ml 
La-phosphatidyl-L-serine, 2.51lg/ml phorbol 12-myristate 13-acetate, 3.5mM dithiothreitol (OTT), 
100llM ATP, 6.5mM magnesium chloride, 50mM Tris-HCI, pH7.5 at 30°C for 30min. The reaction 
was terminated by addition of 5xLaemmii sample buffer and boiled 5 min at 90°C. The proteins 
were then separated by SOS-polyacrylamide gel electrophoresis (PAGE), dried and exposed to 
X-ray films. 
Akt Activity Assay 
Akt kinase activity assay was measured using a commercial available kit from Cell Signaling. 
Briefly, Akt immunoprecipitant were incubated with 11lg GSK-3 fusion protein in the presence of 
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ATP and kinase assay buffer containing 25mM Tris·HCI (pH 7.5), 5mM 0-glycerolphosphate, 
2mM dithiothreitol, 0.1 mM NaN04, 10mM MgCI2 at 30°C for 30 min. Phosphorylation of GSK-3 is 
measured by Western blotting using a phosphor-GSK-3 (Ser21/9) antibody. 
eNOS Activity Assay 
eNOS activity was assayed via measuring NOz/N03 production using colorimetric assay kit from 
Calbiochem. Briefly, incubate recombinant eNOS with/out pretreatment or eNOS 
immunoprecipitant from mouse heart with reaction buffer containing 1.25mM NADPH, 1.25mM 
arginine, 0.5mM CaCI2, 311M tetrahydrobiopterin (BH4), 111M flavin adenine dinucleotide, 111M 
flavin adenine mononucleotide and 25mM Tris-HCI, pH7.4 for 30 min at 30°C. Then nitrate was 
conversed to nitrite with nitrate reductase treatment. Total nitrite was measured by using the 
Griess reaction as modified by Gilliam et al (68). 
Statistical Analysis 
Data are reported as mean±SEM. Differences among the 4 experimental groups were analyzed 
using one-way ANOVA. If the ANOVA showed an overall significance, post hoc contrasts were 
performed with Student t tests for unpaired data using the Bonferroni correction (174). 
38 
CHAPTER III 
Functional proteomic mapping of the myocardial PKC& signaling 
subproteome in the mouse heart: a subcellular compartment 
study 
Abstract 
Functional proteomic analyses have revealed that protein kinase CE (PKCE), a critical mediator of 
cardiac protection, forms multiprotein signaling complexes in the myocardium. We previously 
characterized at least 93 PKCE-associated proteins in the PKC€ signaling subproteome including 
structural proteins, signaling molecules, stress-activated proteins, transcriptional/translational 
factors, metabolism-related proteins, and PKC-binding domain containing proteins. However, 
these studies were performed in the context of the whole myocyte, and information regarding the 
subcellular distribution of these proteins, which is essential for the construction of a cellular map 
of this subproteome, was lacking. The present studies were designed to investigate the 
localization and composition of PKCE complexes in each subcellular compartment and the 
putative mechanisms that govern their assembly. Accordingly, we examined three critical aspects 
of multiprotein complexes in the myocardium: the molecular size of native protein complexes; the 
molecular composition of individual protein complexes, and the assembly of each complex in 
various cellular compartments. Furthermore, the functional significance of these complexes was 
assessed by delineating their formation in the genesis of a cardioprotective phenotype. Using a 
comprehensive functional proteomic strategy that combines various protein isolation, separation, 
and identification techniques, we found that: 1) the cardiac PKC€ signaling subproteome is 
comprised of various multiprotein PKC€ complexes; 2) the native size of each PKCE complex 
differs over a wide range of molecular weight among cytosolic, membrane, nuclear, 
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mitochondrial, and caveolar compartments; 3) different PKC€ complexes appear to have distinct 
molecular compositions, which vary with subcellular location, suggesting that subcellular location 
contributes to the identity of PKC€-associating proteins; and 4) the assembly of these complexes 
is dynamically modulated in the cardioprotected when compared with the normal heart. Taken 
together, our data represent the first comprehensive analysis of subcellular PKC8 protein 




Molecular interactions among proteins serve as essential mechanisms to facilitate the 
transmission of messages within the cell. Functional proteomic analyses of several signal 
transduction systems in various cell types have advanced our understanding of how such 
messages are relayed (91, 97-99, 113, 142, 168, 173). Whereas the majority of previous studies 
have examined the functional interaction of only limited molecules, proteomic analysis of an entire 
subproteome enables delineation of complex molecular interactions in both normal and diseased 
states, providing a more comprehensive picture of how a given signaling network operates. For 
instance, an investigation by Husi et al. identified 77 proteins within the brain NMDA receptor 
complex, which include cytoskeletal, adaptor, and signaling molecules (98, 99). In a different 
study, several proteins, ranging from DNA repair to cytoskeletal regulation, were found to 
undergo expression and/or post-translational alterations following either activation or inhibition of 
the serine/threonine protein kinase MEK, a key component of the ERK pathway (113). 
Recently, our laboratory has used functional proteomics to study myocardial signaling 
(52, 142). These analyses of the cardiac PKCE signaling subproteome revealed that PKCE forms 
multimeric signaling complexes with at least 93 proteins, which can be categorized as structural 
proteins, signaling molecules, stress-responsive proteins, metabolism-related proteins, 
transcription- and translation-related proteins, and PKCE binding domain-containing proteins (52, 
142). Moreover, cardiac protection facilitated by transgenic activation of PKCE was concomitant 
with altered recruitment and post-translational modification of many protein residents within the 
PKCE complexes. Together, these studies indicate that a given signaling element, such as PKCE, 
can interact with and modulate a wide range of proteins, diverse in both structure and biological 
function. 
Recent studies have demonstrated that subcellular compartmentalization is a critical 
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factor in defining signaling specificity (97, 173). Therefore, the delineation of a detailed cellular 
map of a signaling system would be of essential importance to our understanding on how this 
system supports a biological function. Using whole cardiac cell Iysates (52, 142), our previous 
studies identified many molecular participants that comprise the cardiac PKCE signaling 
subproteome, however, information regarding the subcellular localization of PKCE associated 
proteins, which is essential to the mapping of this subproteome, is unknown. The formation and 
activation of specific PKCE signaling complexes at different subcellular compartments has been 
implicated to have significant functional consequences (12, 172, 173). Characterization of the 
subcellular distribution of PKCE complexes should provide key insights into the signaling 
mechanisms underlying the cardiac phenotypes observed in response to PKCE activation. 
Accordingly, in the present study, a systematic examination of PKCE complexes was 
conducted in the cytosolic, nuclear, mitochondrial, membrane, and caveolar subcellular fractions 
of mouse hearts, with regard to both their native sizes and their protein compositions. Moreover, 
the dynamic modulation of each subcellular PKCE signaling complex in response to a phenotypic 
change was also assessed using cardiac protected PKCE transgenic mice that have been 
previously established in our laboratory (Figure 8). Our data provides critical information to the 
mapping of the cardioprotective PKCE signaling subproteome in the murine myocardium. 
42 
Results 
Subcellular fractionation of mouse hearts and isolation of multiprotein PKCE complexes. 
Mouse hearts from transgenic PKCe (TG) and nontransgenic (NTG) littermates were 
homogenized and the Iysates were fractionated by differential centrifugation methods into 
cytosolic, nuclear, mitochondrial, membrane and caveolar fractions. 20 electrophoresis followed 
by silver staining revealed largely disparate patterns of proteins among various subcellular 
fractions (Figure 9). To verify the subcellular fractionation processes, immunoblotting for 
subcellular compartment-specific proteins was carried out for each fraction. The nuclear-specific 
protein NuMA was only found in the nuclear fraction, whereas the sarcolemmal Na+/K+ ATPase 
was primarily localized in the membrane fraction, and the mitochondrial protein prohibitin-1 was 
mainly concentrated in the mitochondria (Figure 10). Finally, cytosolic separation was assessed 
using lactate dehydrogenase (LOH) activity, with >98% of the total LOH activity residing in the 
cytosolic fraction, and only :::;0.85% activity present in any of the other cellular fractions (Figure 
10). Therefore, our subcellular fractionation procedure was largely efficient with minimum cross-
contam ination. 
We next examined PKCE expression in each subcellular fraction from both NTG and TG 
hearts by immunoprecipitating PKCe and then immunoblotting for PKCe. Figure 11 shows that 
PKCe could be efficiently immunoprecipitated from each fraction, which enabled isolation of 
multiprotein PKCe complexes for further studies in a subcellular-specific manner. As expected the 
levels of PKCe in every compartment were considerably higher in the TG mouse hearts when 
compared with the NTG mouse hearts. 
Following immunoprecipitation, multiprotein PKCe complexes from different subcellular 
fractions were eluted and visualized by either 10 SOS-PAGE (Figure 12) or 20 PAGE (Figure 13) 
followed by silver-staining. Figure 12 illustrates significant differences in PKC!:-associated 
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proteins in the cytosolic, nuclear, mitochondrial, and membrane subcellular compartments. These 
differences include the number of proteins present within each subcellular PKCE complex as well 
as the molecular weights of proteins within each subcellular PKCE complex. A similar trend was 
found following 20 separation, examples of which are shown in Figure 13. Multiprotein PKCE 
complexes from cytosolic and nuclear fractions displayed distinct 2D electrophoretic patterns of 
protein spots. Taken together, our results show that each subcellular fraction contains PKCe 
signaling complexes. Moreover, our data show that the number and size of the proteins within the 
PKCe complexes differs in each subcellular compartment. The nature of such differences 
highlights potential subcellular-specific differences in PKCe dependent signal transduction and 
cellular function. 
Delineation of the physical sizes of native multi protein PKCe complexes. 
Having validated the subcellular fractionation and complex isolation procedures, large-scale 
homogenization and fractionation of NTG mouse hearts were performed. Subcellular protein 
mixtures from 15 hearts were analyzed by gel filtration chromatography using a Sephacryl S400 
column to separate intact protein complexes on the basis of their physical size. The presence of 
multiprotein PKCe complexes in the different subcellular fractions was then determined by PKCe 
immunoblotting. Figure 14 shows the chromatographic profiles of PKCe protein complexes in 
cytosolic, membrane, mitochondrial, and nuclear fractions, respectively. Although a significant 
amount of PKCe migrated in the form of either a monomer or a dimer (elution volumes 250-
280ml), especially in the cytosolic and nuclear fractions, the migration pattern of PKCe at lower 
elution volumes demonstrated that PKCe associates with many other proteins in different sized 
complexes. The most striking finding was that the elution profiles of PKCe protein complexes 
were very different in each subcellular fraction, again emphasizing the heterogeneity of 
multiprotein PKCe complexes, both in size and composition, among compartments. 
Individual fractions separated by gel filtration were further analyzed for PKCe complex 
formation. After immunoprecipitation with PKCe antibodies, PKCe complex proteins were eluted 
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and cross-linked with a Sulfo-NHS-LC-Siotin conjugating agent. The biotinylated proteins were 
then separated by 1 D SDS-PAGE and visualized by immunoblotting using a streptavidin-HRP 
conjugate (Figure 15a). The results confirmed that PKCE associates with a battery of proteins in 
the mouse heart. Again, it was evident that the collection of proteins within the PKC£ complexes 
differed across individual subcellular compartments. As expected, the larger complexes were 
found in the lower elution volumes and contained more components in general; whereas the 
smaller complexes were found in the higher elution volumes and hosted fewer proteins. 
To insure that our findings regarding these complexes were not due to protein 
aggregation artifacts, we performed additional experiments to study these multiprotein complexes 
using recombinant GST -PKCE as bait proteins. Cardiac subcellular fractions were incubated with 
GST-PKC£ fusion proteins and allowed to form complexes. These complexes were then isolated 
from the cell lysate by GST pull-down and further fractionated by sucrose gradient centrifugation. 
Gel analysis and immunoblotting of sucrose gradient fractions showed that in all subcellular 
compartments (Figure 15b shows cytosolic as an example), GST-PKC£ forms specific 
multiprotein complexes of varying sizes. The peak sedimentation fraction for PKC£ appeared to 
migrate at -200kDa; however, PKC£ containing fractions were also traced at higher weights 
(>669kDa), showing that large complexes were also formed (Figure 15b). In further complex 
formation tests, analysis of two selective fractions from gel filtration by deoxycholate-buffered 
native gel separation definitively show that PKC£ is present in several high molecular weight 
complexes (>880kDa). Combined with the expression profile of each subcellular fractionate 
generated by gel filtration, these data show that PKC£ forms numerous complexes in each 
compartment that are largely heterogeneous in size and molecular weight (Figure 15c). 
Characterization of protein compositions of subcellular PKC£ complexes in the mouse 
heart 
In order to assess the identity of the proteins within the subcellular PKC£ complexes, PKC£ was 
immunoprecipitated from each fraction and the complexes analyzed by immunoblotting for 
proteins previously demonstrated to be components of the total cardiac PKC£ complex (52, 142). 
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Protein expression profiles of the PKC& signaling complexes in cytosol 
The number of proteins constituting the cytosolic PKCE signaling complex was extensive (Table 
1). Many contractile proteins found in the soluble fraction, such as troponin I and actin, resided in 
the PKCE complex. Interestingly, RACK2 and AKAP79, which are anchoring proteins for several 
kinases, including PKC, were also associated with cytosolic PKCE complexes. Moreover, many 
signaling proteins interacted with cytosolic PKCE including lipid kinases (e.g. PI 3-kinase) (Figure 
16), tyrosine kinases (e.g. Lck, Pyk2), serine/threonine kinases (e.g. Akt, MAPK), and protein 
phosphatases (e.g. PP1, PP2A). Stress-activated proteins involved in the synthesis of low 
molecular weight mediators such as nitric oxide (eNOS) (Figure 16), prostaglandins (COX2), and 
carbon monoxide (HO-1) were also key components, alongside several members of the heat 
shock protein family (HSP70, HSP27). The hypoxia sensitive transcription factor Hif-1 a was also 
found in the cytosolic complex, consistent with the cytoplasmic localization of Hif-1 a in quiescent 
cells (37), as were multiple metabolic proteins, such as creatine kinase. 
Protein expression profiles of the PKC& signaling complexes in nucleus 
The nuclear PKCE complex was as extensive in composition as the cytosolic fraction (Table 1). 
Not surprisingly, the nuclear proteins LAP2, NuMA, and lamin C bound to PKCE in this fraction. A 
similar profile of signaling kinases and stress-activated proteins that was seen in the cytosol was 
also observed in the nuclear signaling complex. However, unlike the soluble fraction, we also 
found the tyrosine kinases Src and BMX in the nuclear PKCE complex. In addition, multiple 
transcriptional proteins resided in the nuclear PKCE complex, including c-Fos, c-Jun, NF-KB, Elk-
1, CREB, and STATs. 
Protein expression profiles of the PKC& signaling complexes in membrane 
Consistent with the hypothesis that RACK proteins mediate PKCE translocation to membranous 
structures, we found both RACK1 and RACK2 in the membrane PKCE complex (Table 1). 
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AKAP79 also co-localized with PKCe complex in this compartment. Other structural proteins in 
the membrane complexes included the intermediate filament protein desmin, the tight junction 
protein villin, the Golgi matrix protein GM130, and W-adaptin, a constituent of clathrin-coated pits. 
Along with the many kinases and stress-activated proteins already observed in the cytosolic and 
nuclear complexes, the cardiac-specific gap junction protein connexin-43 also interacted with 
PKCe in the membrane. 
Protein expression profiles of the PKC& signaling complexes in caveolae 
Although the cytosolic, nuclear, and membranous PKCe signaling complexes contained a large 
number of molecules, we found that the expression profile of proteins in the caveolar PKCe 
complex was by comparison limited (Table 1). The structural protein caveolin-3 was a major 
component of the PKCe complex in this specialized micro-domain. RACK2 and W-adaptin were 
also found. Again, several kinases were associated with PKCe in caveolae including Ras, and 
Akt, the tyrosine kinases Src and Lck, and all three MAPK families. In agreement with previous 
investigations demonstrating strong caveolar localization of NOS (80,151), both eNOS and iNOS 
interacted with PKCe in mouse cardiac caveolae (Figure 7). 
Protein expression profiles of the PKC& signaling complexes in mitochondria 
Our initial analysis revealed number of PKC€ associating proteins in the mitochondrial fraction 
(Table 1). Notably that these proteins include the mitochondrial import protein, prohibitin-1, and 
the mitochondrial metabolic proteins ANT, VDAC, and isocitrate dehydrogenase. In addition, the 
signaling kinase profile of the mitochondrial PKCe complex contained multiple tyrosine kinases, 
as well as members of the MAPK and Akt signaling pathways. There were also a number of 
stress proteins associating with PKCe in the mitochondria, all pertaining to mediator synthesis 
and metabolism, such eNOS (Figure 7) and COX2. 
47 
Modulation of subcellular PKCe complexes size in protected myocardium. 
It has been previously demonstrated that cardiac-specific transgenic activation of PKCE renders 
the mouse heart resistant to ischemiaireperfusion injury (136, 142, 145). In addition, analysis of 
the PKCE complexes from the total cell Iysates of protected hearts and wild type mouse hearts 
showed alterations in the interaction of many proteins with these complexes (52, 142). However, 
it remained unknown what mechanisms regulated the association of given proteins with PKCE. 
Thus, the present study investigated the role of subcellular location as a regulatory determinant of 
the formation of these complexes during phenotypic changes. Gel filtration experiments were 
performed using PKCE TG mice hearts and then compared to those conducted with NTG mouse 
hearts to determine the alterations of native subcellular PKCE complexes during cardiac 
protection. As seen in Figure 6, the native protein profiles of PKCE complexes in TG hearts were 
also subcellular compartment-specific. In general, the size of native PKCE complexes were 
increased in the PKCE cardioprotected hearts, with a concomitant decrease in the free forms, that 
is, the monomeric and dimeric forms, of PKCE, further supporting the concept that protective 
PKCE signaling involves the recruitment of proteins into these complexes. In particular, in the 
cytosolic fraction, PKCE formed putatively several very high molecular weight (>MDa) complexes 
in the TG heart that were not present in the NTG heart. The mitochondrial, membrane, and 
nuclear PKCE profiles also exhibited dramatic changes in the TG mouse hearts compared with 
those in NTG hearts. Taken together, these data indicate that PKCE recruits different molecules 
into the complexes depending on the subcellular location and that the subcellular complexes are 
individually modified in the protected versus the na'fve heart. This finding suggests that this 
subcellular organization of multiprotein signaling complexes contributes to the simultaneous 
modulation of multiple functions that lead to a given phenotype, in this case cardiac protection. 
In addition to modulation of native PKCE complex size, the composition of each PKCE 
complex was altered in a subcellular-specific manner in the TG mouse hearts. Indeed, striking 
variation in the expression profiles of PKCE complexes was observed across different cardiac 
subcellular locations when normal hearts were compared to those protected against ischemic 
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injury (Table 2). Enhanced binding of a variety of signaling and stress-activated molecules to 
PKCe was for the most part subcellular compartment-specific. For example, eNOS was 
upregulated in all the subcellular PKCe complexes whereas the 170kDa isoform of PI 3-kinase 
was only increased in the cytosolic and membrane fractions (Figure 16). Regarding structural 
proteins, the PKCe-selective receptor protein, RACK2 exhibited greater interaction with PKCe in 
both the cytosol and the membrane fraction of the TG mouse hearts, whereas interaction of PKCe 
with the LlM/PDZ-containing protein Oracle, a protein that has been characterized in cardiac 
development (93, 137, 189), was only elevated in the nuclear fraction. The upregulation of these 
specific proteins in specific subcellular complexes points to the ability of PKCe to modulate 
multiple, discrete cellular functions. 
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Discussion 
Although several efforts in whole organelle proteomic analyses of mitochondria (12, 77, 
118), Golgi (17, 178) and other subcellular fractions (36, 90, 109, 126, 131, 139) have achieved 
fruitful results, comprehensive characterization of the entire proteome of a particular organelle 
remains a Herculean task. Major challenges include the dynamic nature of these organelle 
proteomes with respect to the changes of time and cellular functions. In contrast, studies focusing 
on the examination of specific subproteomes, such as the PKCE signaling system, will target a 
sub-group of proteins on the basis of the specific biological functions they perform and will define 
temporal alterations of these proteins (during the time course of a phenotype change). 
Consequently, this approach is more focused and will enable us to circumvent the 
aforementioned challenges. In accord with this concept, simultaneous proteomic analysis of a 
particular subproteome in all subcellular compartments will illustrate a cellular map of this 
subproteome, and would offer important novel insights. 
Consequently, the primary objectives of the present investigation were to delineate the 
subcellular distribution of the PKC€ signaling subproteome and to understand how assembly of 
this subproteome is modulated during cardioprotection. We hereby report that the PKC€ signaling 
subproteome is comprised of various multiprotein PKC€ signaling complexes; these complexes 
differ in their native molecular size, and the formation of these complexes is modulated on a 
subcellular basis within cardiac cells. To our knowledge, this is the first study to demonstrate the 
formation of native, signaling kinase (PKCE)-based, multiprotein complexes, and to define how 
modulation of these complexes directly correlates with a specific phenotype (cardioprotection). 
This study provides three lines of novel information: 1) these data show differential regulation of 
multiprotein complex assembly across subcellular locations, suggesting that this subcellular 
organization of distinct multiprotein complexes may serve as a mechanism for signal 
transduction; 2) these data demonstrate that a signaling kinase, namely PKCE, can form 
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protein complexes with numerous other functionally diverse proteins, and that the distinct 
molecular components of these complexes appear to be modulated in a stimulus and subcellular 
location-specific manner; and most importantly, 3) these findings suggest that analysis of intact, 
non-denatured multiprotein complexes is an essential step to further our understanding of the 
manner in which these complexes transduce signals in normal and diseased organs. 
We achieved mapping of the PKCE' subproteome using two complimentary approaches. 
The first approach encompasses the biochemical methods of gel filtration, native gels, and 2D 
electrophoresis, which enabled the determination of the size and composition of the protein 
complexes. The data presented herein shows clearly that PKCE forms multiprotein complexes 
that contain many components. Size fractionation of subcellular proteins using gel filtration 
showed a dynamic size range of PKCE complexes, which differ cross subcellular compartments, 
and are dynamically modulated in the non-transgenic and cardioprotected PKCE transgenic 
hearts (Figure 14). Consistent with these findings, GST-PKCE pull-down and sedimentation 
sucrose gradient analysis illustrate that multiprotein PKCE complexes are heterogeneous and 
multimeric in nature in vivo and in vitro. Similarly, the 2D electrophoretic display of PKCE 
complexes from cytosol and nuclear subcellular fractions yielded different patterns (see Figure 
13c) concurrent with the hypothesiS that each subcellular fraction contains distinct PKCE 
complexes. 
The second approach taken was the systematic identification of proteins within individual 
subcellular compartmentalized PKCE complexes, using classical immunoprecipitation and 
immunoblotting techniques (Table 1 and 2). The majority of previous proteomic studies have 
relied on mass spectrometry for protein identification. Indeed, using this strategy, our laboratory 
has previously identified 93 proteins in the PKCE signaling subproteome (52, 142). However, in 
view of the concerns of the sensitivity of our established mass spectrometry data, we have 
performed a substantial amount of immunoblotting analyses to verify and substantively confirm 
these results (52, 142). 
The data revealed that the number and nature of specific proteins present within a PKCE 
complex was dependent upon the subcellular location (see Table 1). For example, the cytosolic 
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PKCE complexes contained -50 proteins from all of the functional groups (signaling, structural, 
stress-activated, transcription, metabolism, and PKC binding domain). In stark contrast, the 
caveolar PKCE complexes contained only 13 proteins that were primarily signaling and structural 
molecules; presumably a direct reflection of the specialized nature of this particular subcellular 
compartment. A somewhat surprising finding was that a large number of PKCE-associated 
proteins were found outside of their normal subcellular context. The specific PKCE anchor protein 
RACK2 is thought to localize to cytosolic and membranous compartments such as the 
sarcolemma and Golgi (41) and indeed co-localized with PKCE in these fractions. However, it was 
also found to be a key component of the mitochondrial, nuclear, and caveolar complexes. This is 
an important observation, as it represents a means by which PKCE can localize to these 
organelles, as has been described during cardiac protection. Similarly, we found that eNOS 
interacts with PKCE in every compartment (see Figure 16). Many studies have demonstrated the 
cytosolic and particularly membrane/caveolar localization of eNOS in cardiac cells (24, 180), and 
thus, the interaction of eNOS with PKCE in these compartments was expected. However, eNOS 
also co-localized with PKCE in the nuclear and mitochondrial fractions. Nuclear translocation of 
eNOS in response to VEGF and estradiol (54) has been reported and the formation of nuclear 
PKCE-eNOS complexes may allow a more direct modulation of transcription by nitric oxide. Nitric 
oxide is able to permeate the mitochondrial membrane and can influence the function of many 
components of oxidative phosphorylation (31). Consequently, mitochondrial PKCE-eNOS 
complexes may enable PKCE to regulate myocardial energy. The functional importance of 
signaling between PKCE and eNOS has been further elucidated in detail and these findings will 
be presented in the subsequent Chapter. These examples show that, in addition to further 
delineating the cardiac PKCE signaling system, the present study provides novel insight into the 
subcellular expression of a number of molecules and therefore evidence for heretofore unknown 
functions of PKCE. 
The finding that the protein composition of these subcellular PKC€ complexes was 
modulated during cardiac protection serves as important evidence for the role of these complexes 
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to regulate phenotype. As shown in our previous study (142) many of the PKCE associated 
proteins have been implicated in protection of the heart against ischemic injury cardioprotection. 
To name a few, Src (146,160), Lck (144,145), Akt (39), MAPKs (12,141), COX2 (78,158), NOS 
(78, 181), connexin-43 (47), NF-KB (115,181), HO-1 (184), and HIF-1 (37) have all been shown 
to play protective roles in the heart. Interestingly, compartment-specific alterations in the 
association of these known cardiac protective proteins within PKCf complexes were saliently 
observed in the present study. For example, recruiting NF-KB to PKCE was only observed in the 
nuclear fraction whereas increased binding to the caveolin-3 was only found in the caveolar 
fraction. Again, these data are consistent with the specialized functions of the proteins involved: 
transcription in the case of NF-KB and the structure/regulation of caveolae in the case of caveolin-
3. 
In summary, the present study demonstrates that different subcellular locations within the 
myocardium contain PKCE complexes with various native sizes and distinct molecular 
components, suggesting that specific cellular tasks at different subcellular locations are facilitated 
by regulation of these protein complexes. Furthermore, these subcellular complexes are 
independently modulated in terms of size and composition when the myocardium is protected 
against ischemic insult. Taken together, these findings support the notion that subcellular-specific 
organization of multiprotein complexes may serve as a mechanism by which the cell controls its 
phenotype. 
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Figure 8. Flow chart for isolation and visualization of PKCI> multi protein signaling 
complexes - experimental strategy for Chapter III Mouse hearts were homogenized 
and separated into different subcellular fractions. Then gel filtration chromatography, 
PKCE immunoprecipitation or GST-PKCE affinity pull down assay were applied to isolate 
protein complexes. Different methods were subjected to visualize PKCE multiprotein 
complexes, leading to obtain various data shown in the following figures. 
54 
Tissue Homogenization and 
Isolation of Subcellular 
Compartments 




Isolation I Separation of 
Protein Complexes Gel Filtration Chromatography PKCE IP 
~ 







































Figure 15 c 
lr) 
lr) 
Figure 9. Two dimensional (20) electrophoresis separating protein mixtures 
obtained from mouse heart cytosolic (left) and membrane (right) subcellular 
fractions. The mouse hearts were homogenized and separated into cytosolic, 
membrane, mitochondrial and nuclear fractions. Subcellular extracts from cytosolic and 
membrane fractions were loaded onto immobilized pH gradient (IPG) strips and 
subjected to isoelectric focusing (pi) in the first dimension. The IPG strips were re-
equilibrated and subjected to SDS-PAGE for the second dimension by molecular weight 
(MW). Proteins were then visualized by silver staining 
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Figure 10. Immunoblotting analysis of known marker proteins in subcellular 
fractions. Subcellular-specific marker proteins were used to verify the separation 
procedure, such as nuclear-specific NuMA (upper panel); membrane-specific Na+/K+ 
ATPase (middle panel); and mitochondrial-specific Prohibitin-1 (lower panel). Cytosolic-
specific lactate dehydrogenase (LDH) activity was also measured in each subcellular 
fraction (graph). 
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Figure 11. Characterization of multiprotein PKCe signaling complexes-A. Protein 
from non-transgenic (NTG) and PKCe transgenic (TG) mouse hearts were 
immunoprecipitated (IP) with PKCE antibodies, separated by 1 D SDS-PAGE, and 
immunoblotted (18) with PKCE antibodies. This figure showed that PKCE could be 
efficiently immunoprecipitated from each subcellular fraction. Moreover, as expected that 
PKCE protein expression level in every compartment were higher in PKCE transgenic 
mice when compared with NTG. 
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Figure 12. Characterization of multiprotein PKCe signaling complexes-B. 
Subcellular extracts were subjected to PKCE immunoprecipitation to isolate PKCE protein 
complexes. Then PKCE associated proteins were separated by 1 D SDS-PAGE, and 
visualized by silver staining. PKCE associated with many proteins, and the patterns of 
polypeptides were significantly different in each subcellular fraction. The differences were 
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Figure 13. Characterization of multiprotein PKCe signaling complexes-C. 
Subcellular extracts were subjected to PKCe immunoprecipitation to isolate PKCe protein 
complexes. Then PKCe associated proteins were separated by 2D SDS-PAGE, and 
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Figure 14. Demonstration of PKCE multiprotein signaling complexes by liquid 
chromatography. Subcellular protein Iysates (-10mg) of both non-transgenic (NTG) 
and PKCE transgenic (TG) hearts were fractionated by gel filtration. Proteins from 
elution fractions were precipitated and PKCE signaling complexes visualized by 
immunoblotting. All elution fractions were normalized for PKCE expression using 100/1g 
NTG heart Iysates as internal control. Bar graph indicates the presence of PKCE 
multiprotein complexes. The elution profiles of PKCE complexes were different in 
different subcellular compartments. Compared with non-transgenic animals, the elution 
profiles of PKCE complexes were shifted toward higher PKCE complexes in PKCE-
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Figure 15. Determination of the native size of multi protein PKCB complexes. 
(a) The 120th and 180th elution fractions from the gel filtration column were 
immunoprecipitated with PKCe antibodies. PKCE protein complexes were biotinylated 
with a trifunctional cross-linking agent (EZ-Link Sulfo-NHS-LC-Biotin [Pierce]). The 
biotinylated proteins were separated by 1 D SDS-PAGE and visualized by 
immunoblotting using a streptavidin-HRP conjugate. (b) Native PAGE analysis of 180th 
elution fraction. Left column: various cellular multiprotein complexes visualized by 
native PAGE followed by silver staining. Right column: the PKC€ protein complexes 
visualized by native PAGE followed by immunoblotting (IB) for PKC€ (indicated by 
arrows). (c) Sedimentation sucrose gradient analysis of GST-PKCe-associated 
proteins. GST-PKCe fusion proteins were used for the affinity pull down PKC€ 
complexes from cytosol. Subsequently, various sizes of GST-isolated protein mixtures 
were separated by sucrose gradient (10-30%). Upper panel: PKC€ immunoblotting of 
the sucrose gradient fractions collected (1-to-18), arrows indicating the molecular 
weight range of PKC€ multiprotein complexes (upper arrows at 232kDa and 669kDa, 
respectively). Lower panel: sucrose gradient fractions (1-to-18) were further separated 
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Figure 16. Identification of the molecular components of the multiprotein PKCE 
complexes: examples of eNOS and p170 PI 3-Kinase. 
Proteins from non-transgenic (NTG) and PKC£ transgenic (TG) mouse hearts were 
separated into cytosolic, membrane, mitochondrial, nuclear and caveolae fractions. 
Then subcellular extracts were immunoprecipitated (IP) using PKC£ antibodies, 
separated by 1 D SDS-PAGE and immunoblotted (18) with eNOS antibodies (left 
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Table 1 : PKCB signaling complex proteins in subcellular fractions 
Subcellular 
Mr. Fractionations 
(kOa) pi Known Function C N M Mit Cay 
Structural proteins 
Troponin I 24 9.6 Contractile protein + 
Troponin T 35 5.2 Contractile protein + 
Oesmin 53 5.2 Cytoskeletal protein + + 
RACK1 36 7.6 PKC binding protein + + 
RACK2 102 5.2 PKC binding protein + + + + + 
Villin 95 5.7 Cytoskeletal protein + + 
W-Adaptin 106 5.0 Intracellular transport adaptor protein + + + 
AKAP79 79 5.1 Anchoring protein + + + + 
Vimentin 54 5.1 Intermediate filament + + + 
Cadherin-2 129 4.9 Cell junction adhesions, Ca++ regulated + + + + 
Lamin C 65 6.4 Nuclear intermediate filament + + + 
Oracle1/2 70/80 8.0 Cardiac development. LlM/POZ + + + + 
domains 
Vinculin 117 5.7 Focal adhesion protein + + 
Glucose-regulated 75 5.1 Molecular chaperone + + 
protein 
Alpha-Actinin-2 104 5.4 Intermediate filament, Z band + + + 
Lap2 75 8.6 Nuclear structural protein + 
NMA 240 5. Nuclear protein involved in mitosis + + 
GM130 130 5.0 Golgi matrix protein + 
Prohibitin-1 30 5.6 Mitochondrial chaperone protein + 
Caveolin-3 18 5.5 Cardiac caveolae structural protein + 
Signaling proteins 
Pl3-kinase 170 8.3 Phosphoinositide lipid ~~inase + + + 
Pyk2 116 5.9 FAK tyrosine kinase family + + + 
Lck 56 5.2 Src family tyrosine kinase + + + + 
Src 60 7.9 Src family tyrosine kinase + + + + + 
PKB/Akt 59 5.6 Stress-activated kinase + + + + + 
p38 MAPK 38 5.5 Stress-activated kinase + + + + + 
JNK1/2 46/54 7.6/6.2 Stress-activated kinase + + + + + 
ERK1/2 44/42 6.0/8.9 Receptor and stress-activated kinase + + + + + 
MEK1 45 6.2 Upstream activator of ERK + + 
Ras 21 6.2 GTPase that activates MAPK pathways + + + + + 
Connexin-43 43 9.0 Cardiac gap junction protein + + 
POK1 63 6.7 SerlThr kinase + + + + 
PP2A 36 5.3 SerlThr kinase phosphatase + + + 
PP1 38 5.9 SerlThr kinase phosphatase + + + 
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PI-3-kinase 85 6.0 Phosphoinositide lipid kinase + + + + 
BMX 80 8.6 Tec family tyrosine kinase + + + 
Stress-activated 
proteins 
iNOS 130 7.8 Inducible nitric oxide synthase + + + + + 
eNOS 140 6.6 Constitutive nitric oxide synthase + + + + + 
COX-2 70 7.0 Prostaglandin H synthase + + + + 
Heme-oxygenase 1 32 6.1 Stress-activated protein + + + 
Aldose reductase 36 6.7 Osmotic stress-activated protein + + + 
Heat shock protein 70 70 5.5 Molecular chaperone + + + + 
Heat shock protein 27 25 6.4 Molecular chaperone + + + 
aB-cystailin 20 7.3 Molecular chaperone + + + 
Heat shock protein 60 61 6.3 Molecular chaperone + + 
Metabolism-related 
proteins 
ANT1/2 33 9.7 ATP/ADP exchanger + + 
Creatine kinase 43 6.6 Reversibly phosphorylates creatine, + 
energy storage 
GAPDH 36 8.4 Glycolysis + 
Isocitrate DH 38 6.0 Citric acid cycle + + + 





Histone H4 14 11.3 DNA binding to facilitate chromatin + + 
structure 
hnRNP H1 49 5.9 mRNA processing and regulation + 
hnRNP K 51 5.3 mRNA processing and regulation + + 
Ribonucleoprotein 37 6.4 MRNA processing and regulation, heat + + + 
shock, splicing 
NFKB p65 65 5.5 Activated by stress and inflammation + + 
HIF-1a 100 5.2 Hypoxia-inducible transcription factor + + 
c-Fos 55 4.8 Proto-oncogene, part of AP1 complex + 
c-Jun 36 8.9 Proto-oncogene, part of AP1 complex + 
CREB 43 5.4 Binds cAMP response element + 
Elk 45 6.3 Activated by MAPK family kinases + 
STAT 1 87 5.4 Activated by JAK family kinases + 
STAT3 88 5.9 Activated by JAK family kinases + + 
c-Myc 50 5.5 Proto-oncogene + + 
hnRNP a2/b1 37 9.0 MRNA processing and regulation + 
All pi values were estimated using the ExPASy compute pl/MW tool available on the web. 
C=Cytosol; N=Nuclei,; M=Membrane; Mit=Mitochondria; Cav=Caveolae. 
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Table 2 : Altered protein expression in PKCE signaling complex proteins in subcellular 
fractions 
Subcellular Fractionations 
Cytosol Nuclear Membrane Mitochondria Caveolae 
Structural proteins 







PI 3-kinase (85kDa) ++ 
Pyk2 kinase ++ 
Lck ++ ++ ++ 
Src ++ 
PKB/Akt ++ ++ 
p38 MAPK ++ 
JNK1/2 ++ ++ 
ERK1/2 ++ ++ 
Ras ++ +++ +++ 
PDK1 ++ ++ 
BMX ++ ++ ++ 
PI 3-kinase (170kDa) ++ ++ 
Stress-activated proteins 
eNOS ++ ++ ++ ++ ++ 
Aldose reductase ++ ++ 








The "++" signs indicate increased expression of proteins in various subcellular compartments in 




Functional proteomic analysis of myocardial PKCs-Akt-
eNOS signaling modules during cardioprotection 
Abstract 
Having established in the studies described in the foregoing Chapter that PKCE complexes are 
differentially regulated in a subcellular compartment specific fashion, we next wanted to 
determine the manner in which individual signal transduction modules are formed to transducer 
signaling within these complexes. 
Among the 93 different PKCE-associated proteins that we identified to date, the protective 
kinase Akt and stress-activated protein endothelial nitric oxide synthase (eNOS) are of 
importance due to their independent abilities to promote cell survival and prevent cell death. Their 
co-localization within the PKCE protein complex suggests that PKCE, Akt and eNOS may form 
signaling modules for the regulation of nitric oxide (NO) production and hence the manifestation 
of the cardioprotective phenotype. Accordingly, using functional proteomic tools, we found that: 
(1) PKCE, Akt and eNOS interact and form signaling modules both in vitro and in vivo; activation 
of either PKCE or Akt enhances the formation of PKCE-Akt-eNOS signaling modules; moreover, 
the formation of these signaling modules is dynamically regulated during cardioprotection; (2) 
PKCE directly phosphorylates and enhances activation of Akt in vitro, and PKCE transgenesis 
increases both phosphorylation and activation of Akt in vivo; (3) PKCE can also directly 
phosphorylate eNOS in vitro, and this phosphorylation enhances eNOS activity. Furthermore, 
overexpression of PKCE in vivo increased phosphorylation of eNOS at Ser1177, representing 
increased eNOS activity. This study characterizes, for the first time, functional as well as physical 
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coupling of PKCE, Akt, and eNOS in the heart, and provides novel information regarding the 
formation and modulation of PKCE-Akt-eNOS signaling modules during cardioprotection. 
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Introduction 
The proteome is proposed to be composed of multiple integrated functional subproteomes, each 
of which is organized to facilitate a unique function. Moreover, specific signaling modules are 
formed within these subproteomes in response to different stimuli (82, 99, 170). In particular, our 
laboratory has focused on the PKCE subproteome, and the modules present within. PKCE plays a 
critical role in the genesis of cardioprotection against myocardial ischemic injury (49, 75, 140, 
147), and cardiac-specific expression of PKCE is cardioprotective (142). Recent studies in our 
laboratory have found that PKCE forms multimeric signaling complexes with at least 93 proteins, 
including structural proteins, stress-activated proteins, proteins associated with transcription and 
translation, proteins involved in cellular metabolism, and various kinases and phosphatases (52, 
142, 160, 172). Furthermore, the assembly of these multiprotein PKCE complexes is dynamically 
modulated in PKCE-transgenic mouse hearts, which serves as important evidence for the role of 
these complexes in regulating the cardioprotective phenotype. Among the 93 known protein 
partners, Akt and eNOS are of great interest as they are well established to independently 
promote cell survival and prevent cell death in response to various forms of stress (16, 42, 63, 
182). 
Previous studies in non-cardiac cells demonstrate physical and functional interactions 
among PKC, Akt and eNOS. Akt can directly interact and phosphorylate eNOS on Ser1177 (63). 
Akt co-immunoprecipitates with PKCI:;; or PKCt (48, 119), and the PH domain of Akt has been 
implicated as the binding side for PKCI:;; to Akt1 and Akt3 (110). Li et al show that overexpression 
of PKCu stimulates Akt activity and suppresses apoptosis induced by interleukin 3 withdrawals in 
myeloid progenitor cells (114). In contrast, Wen and colleagues (176) report that in A549 and 
HEK293 cells, the phosphatidylinositol 3-kinase/Akt signaling pathway is negatively regulated by 
PKC. Moreover, it is reported that activation of PKC inhibited eNOS activity by attenuating eNOS 
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phosphorylation on Ser1177 and increasing phosphorylation of Thr495 in endothelial cells (123, 
124). However, despite this information nothing is known regarding the formation and regulation 
of PKCE-Akt-eNOS signaling modules in myocytes, especially during cardioprotection. Therefore, 
a comprehensive investigation needs to be implemented to draw a clearer picture of the temporal 
and spatial relationship among PKCE, Akt and eNOS in the regulation of NO production and the 
genesis of cardioprotection. 
Accordingly, we hypothesized that PKCE, Akt and eNOS form a signaling module within 
the mouse heart, the assembly and activation of which contributes to the genesis of 
cardioprotection. By applying functional proteomic tools, we examined the PKCE-Akt-eNOS 
signaling modules in vitro and in vivo in two major aspects: molecular architecture, as defined by 
protein-protein interactions; and module regulation, as defined by posttranslational modification 
and alteration of activity of each component of PKCE-Akt-eNOS signaling. Moreover, using mice 
with cardiac-specific expression of active PKCE, we also assessed how these signaling modules 
are regulated during cardioprotection. 
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Results 
PKCe can directly interact with Akt and eNOS in vitro 
To examine the ability of PKCe to directly interact with Akt or eNOS, GST-PKCE fusion 
proteins were incubated with recombinant Akt or eNOS, followed by SDS-PAGE and Western 
blotting for Akt or eNOS. Figure 17 demonstrates that PKCE directly interacts with Akt in vitro. 
Moreover, we also found that GST-PKCE preferentially interacts with recombinant active Akt that 
is expressed by baculovirus in Sf21 insect cells and activated with GST-MAPKAPK2 and PDK1, 
as compared to a much weaker interaction with inactive Akt from insect cells without treatment. 
Furthermore, we assessed the domain-specificity of the interaction between Akt and PKCE by 
incubating GST-PKCE with recombinant Akt protein with or without PH domain. We found that the 
interaction between GST-PKCE and mutant, PH domain deficient, Akt was significantly 
attenuated, suggesting that this region of Akt is responsible for its interaction with PKCE (Figure 
17a and b). Taken together, our data indicated that PKCE directly interacts with Akt primarily 
through binding Akt's PH domain. Using a similar approach, we also found that GST-PKCE could 
also physically directly interact with eNOS, as shown in Figure 17c. 
Since PKCE can directly interact with Akt and eNOS in vitro in a binary sense, we then 
assessed the ability of these molecules to enhance their association with each other beyond that 
seen in the foregoing pair-wise experiments. Recombinant Akt and eNOS were incubated with or 
without PKCE followed by eNOS immunoprecipitation and Akt immunoblotting. We found that 
recruitment of PKCE increased the binding affinity of eNOS with Akt (Figure 18a left). To examine 
the effect of PKCE activity on this interaction, recombinant PKCE was next incubated with Akt and 
eNOS in the presence or absence of potent PKC activators phorbol ester (PMA) and 
phosphatidylserine (PS) followed by immunoprecipitation of PKCE and blotting for Akt or eNOS. 
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Figure 18a (right) showed that although PKCE formed protein complexes with Akt and eNOS in 
the absence of PKC activators, PMAlPS-activated PKCE exhibited a much high affinity for Akt and 
eNOS, indicating that activation of PKCE enhanced its interaction with both Akt and eNOS. In 
addition, we tested the effect of Akt on the interaction of PKCE and eNOS by incubating PKCE 
and eNOS with active or inactive Akt recombinant proteins. Similar to the results obtained for 
PKCE, activation of Akt was found to enhance its interaction with PKCE and eNOS, and its ability 
to facilitate interactions between PKCE and eNOS (Figure 18b). 
PKCe interacts with Akt and eNOS in vivo 
Previous studies have shown that Akt and eNOS are present in cardiac PKCE-signaling 
complexes, as assessed by both GST-PKCE affinity pull down assay and PKCE 
immunoprecipitation (52, 142), indicating that PKCE can interact with Akt and eNOS in vivo. In the 
present study, using PKCE immunoprecipitation, we found that although all three isoforms of Akt 
are present in the mouse heart, only Akt1 and Akt2 interact with PKCE (Data not shown). 
To assess the formation of PKCE-Akt-eNOS signaling modules in vivo, mouse hearts were 
homogenized and subjected to gel filtration chromatography using a Sephacryl S400 column. 
This process separates intact myocardial protein complexes on the basis of their physical size. 
Individual fractions from liquid chromatography were next immunoprecipitated with PKCE 
antibodies. The PKCE immuno-complexes were then separated by SDS-PAGE and blotted for 
PKCE, Akt and eNOS. Figure 19a shows the chromatographic profiles of PKCE-associated Akt 
and eNOS protein complexes in normal mouse hearts. We found that Akt and eNOS co-
precipitated with PKCE in multiple fractions, indicating that PKCE, Akt and eNOS interacted with 
each other in a variety of different sized PKCE-containing complexes. Furthermore, compared 
with the profiles of non-transgenic mouse hearts, we found that the expression profiles of PKCE-
Akt-eNOS signaling modules in PKCE-cardioprotective transgenic mice were shifted towards 
higher molecular weight complexes (Figure 19b), indicating the dynamic modulation of PKCE-Akt-
eNOS signaling modules in vivo during cardioprotection. 
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PKCE can directly phosphorylate Akt and eNOS and enhance their activities in vitro. 
Based on the above findings, we further investigated the effect of PKCE activation on the 
formation of PKCE-Akt-eNOS modules in vitro. First, we assessed whether PKCE could directly 
phosphorylate Akt and/or eNOS in vitro. Recombinant Akt or eNOS were incubated with 
recombinant PKCE in the presence of the PKC activators, phorbol ester (PMA) and 
phosphatidylserine (PS), and radiolabeled p32_y_ATP. After SOS-PAGE separation, 
phosphorylation was visualized by autoradiography. We found that PKCE could directly 
phosphorylate both Akt and eNOS (Figure 20a). 
Next, we further tested the effects of these PKCE-induced phosphorylation modifications 
on the activation status of Akt and eNOS. After incubating recombinant inactive Akt with PKCE, 
Akt activity was assessed by its ability to phosphorylate GSK-3p. We found that Akt activation 
was dramatically increased with the PKCE treatment (Figure 20b) as compared with inactive Akt 
alone, indicating that activated PKCE dramatically enhances Akt activity in vitro. Similarly, we 
found that PKCE treatment significantly enhanced eNOS activity, as measured by nitrate/nitrite 
production, (178.8±11 %, P<0.05 vs eNOS only) when compared with non-treatment (Figure 20b). 
Studies by other investigators indicate that Akt is activated by phosphorylation of Thr308 
within its activation loop which serves to stabilize the molecule in its active confirmation. 
Subsequently, phosphorylation of serine 473 (Ser473) at the C-terminus is essential for full 
activation of Akt. While it is well known that POK1 is responsible for Thr308 phosphorylation, the 
upstream kinases that catalyze the phosphorylation of Ser473 is unclear. Because our initial 
studies demonstrated signal transduction between PKCE and Akt, we next tested whether PKCE 
could be a putative POK2 that targets Ser473 by using the site-specific phospho-antibody of Akt 
after the PKCE treatment. Figure 21 shows that addition of recombinant PKCE significantly 
increased Ser473 phosphorylation on Akt as compared with that of inactive Akt alone, indicating 
that in vitro, PKCE directly phosphorylates Akt on Ser473. 
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PKCe transgenesis enhances phosphorylation and activation of Akt and eNOS in vivo 
In addition to the in vitro phosphorylation experiments, we also examined the phosphorylation of 
Akt and eNOS in vivo. PKCr::-cardioprotected transgenic mice hearts were used to test the effect 
of activation of PKCe on Akt by examining the two conserved phosphorylation sites of Akt. Using 
the site-specific phospho-antibodies of Akt, we found that phosphorylation of Akt on both 
activation sites Thr308 (336.1±15.1% vs NTG) and Ser473 (181.3±18.2% vs NTG), was 
significantly increased in PKCr:: transgenic mice when compared with non-transgenic animals. 
These post-translational modification changes occurred in the absence of a total change in Akt 
protein expression (Figure 22a). Interestingly, total cardiac cellular Akt activity was increased in 
PKCr:: cardioprotected mice (Figure 22b top panel). Moreover, when we examined PKCr::-
associated Akt activity (PKCr:: complexes were isolated by immunoprecipitation and Akt kinase 
activity assays performed), we found a surprising augmentation of Akt activity, considerably 
greater than that seen in the total lysate pool, when Akt was associated with PKCr:: (Figure 22b 
lower panel). These data support the concept that module formation between PKCr:: and Akt 
accomplishes signal transduction by post-translationally modifying Akt and increasing its activity 
on downstream substrates. 
It is well documented that once Akt is activated, it can phosphorylate eNOS at serine 
1177(Ser1177) resulting in activation of eNOS and the production of nitric oxide. Therefore, we 
examined the phosphorylation of eNOS in vivo in the PKCr:: transgenic mice hearts. 
Phosphorylation of eNOS on Ser1177 (407.8±43.7% vs NTG) was enhanced in the PKCr:: 
transgenic mice (Figure 23), indicating that overexpression of PKCr:: increased eNOS activity in 
vivo. Meanwhile, total eNOS protein expression was also slightly increased (140.9±7.2% vs NTG) 
in PKCr:: transgenic mice. 
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Discussion 
Recent studies suggest that cellular biological functions, such as signal transduction, are 
accomplished by multi-protein complexes, which contain within them modules that are composed 
of several species of interacting molecules. Modules may have discrete functions engendered 
from the interactions among their individual components. Understanding how these molecules 
interact and regulate each other is critical in order to comprehend the specific biological function 
of such modules. Accordingly, in this study, we hypothesized that PKCE forms functional signaling 
modules with Akt and eNOS, and that the assembly and activation of these modules contributes 
to the genesis of cardioprotection. Using functional proteomic approaches, we tested the 
hypothesis in two different aspects: molecular architecture and module regulation. There are 
several important findings in this investigation. First, PKCE interacts with Akt and eNOS both in 
vitro and in vivo, and these interactions are promoted by enhanced activation of PKCE. Second, 
PKCE forms various sizes of signaling modules with Akt and eNOS, which are dynamically 
regulated in PKCE transgenic mice during cardioprotection. Third, PKCE directly phosphorylates 
Akt and eNOS, resulting in increased Akt and eNOS activation in vitro, whereas in vivo, 
overexpression of PKCE increases both phosphorylation and activation of Akt and eNOS, 
especially PKCE-associated Akt activation. This study characterizes, for the first time, physical 
and functional coupling of PKCE, Akt, and eNOS in the mouse heart, and provides novel 
information regarding the formation and modulation of PKCE-Akt-eNOS signaling modules during 
cardioprotection. 
Spatial distribution of PKCe-Akt-eNOS signaling modules 
In addition to the molecular architecture of signaling modules and their regulation, the 
spatial distribution of a module within the cell is another important aspect to understand the 
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function of these signaling units. Using classical immunoprecipitation and immunoblotting 
techniques, our previous studies already determined the subcellular distributions of PKCE-Akt-
eNOS signaling modules both in normal and cardioprotective hearts. We found that, 
accompanying the increased protein expression of PKCE in multiple fractions (cytosol, 
membrane, mitochondria, nuclear, and caveolae), protein expression of eNOS in PKCE 
complexes was also increased in all five subcellular fractions. In contrast, Akt expression was 
only found to be increased in PKCE-associated membrane and nuclear fractions in 
cardioprotected mouse hearts. Therefore, although PKCE-Akt-eNOS modules were found to be 
existent in multiple fractions, increased formation of this module occurred only in membrane and 
nuclear fractions during cardioprotection, implicating subcellular compartment-specific functions 
of PKCE-Akt-eNOS modules in normal and protected hearts. For example, many studies have 
demonstrated that translocation to the membrane is an important regulatory action for activated 
PKCE and Akt. Moreover, eNOS is largely membrane-associated as a result of the N-terminal 
myristoylation and palmitoylation of this molecule (30). Thus, we expected to see the increased 
formation of PKCE-Akt-eNOS signaling modules in membrane fractions during cardioprotection. 
Increased formation of PKCE-Akt-eNOS signlaing modules in nuclear fractions in PKCE transgenic 
mice may modify activation of transcription factors or other targets within nucleus fraction and 
thereby regulate cardioprotective gene/protein synthesis. 
PKCe forms different sizes of signaling modules with Akt and eNOS 
Revealing the existence of intact, non-denatured, multiprotein PKCE-Akt-eNOS modules 
is an important step to confirm our hypothesis regarding the involvement of these modules in 
signal transduction. Using biochemical methods of gel filtration, PKCE immunoprecipitation, we 
have delineated the physical characteristics of PKCE-Akt-eNOS signaling modules. Our data 
clearly show that PKCE co-exists with Akt and eNOS in protein complexes of varying sizes in the 
mouse heart. Moreover, during PKCE-induced cardioprotection, the profile of PKCE-Akt-eNOS 
modules is dynamically regulated. These data provide PKCE-Akt-eNOS modules shifting to larger 
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molecular weight complexes. These data provide a solid base for our future study to explore the 
composition and interaction of each PKCe-Akt-eNOS signaling module. 
To confirm the presence of PKCe-Akt-eNOS signaling modules in vivo, in addition to 
separation protein complexes following PKCe immunoprecipitation, we used GST-PKCe pull down 
assays to form new PKCe complexes, and then separated the complexes by deoxycholate-
buffered native gel electrophoresis followed by Akt and eNOS immunoblotting. It is found that 
only a few of PKCe-Akt-eNOS modules had been formed in non-transgenic mouse hearts, 
whereas, a high molecular weight PKCe-Akt-eNOS signaling module was found in the PKCE-
cardioprotected transgenic mice. The size of this macromolecular complex was estimated to be 
greater than 880kDa, as determined by comparison to protein markers (data not show). 
Interestingly, we found significantly fewer PKCe-Akt-eNOS modules via the native PAGE 
approach as compared with the results from the gel filtration technique. The difference between 
these results is most likely due to the fact that addition of exogenous PKCe will likely disrupt 
endogenous preexisting complexes while also inducing formation of other complexes. Thus, 
these techniques (immunoprecipitation and GST-based affinity pull-down) appear to be 
complementary, in that they identify non-overlapping pools of protein interactions. 
Since PKCe interacts with Akt and eNOS to form varying sizes of complexes, how do 
these three molecules interact? Several investigators have shown that PH domain is the 
preferred interaction domain for PKC binding to Akt. In our study, we found that PKCe preferred to 
interact with Akt via its PH domain which was congruous with previous studies in non-cardiac 
cells (18). Moreover, we found that PH domain of Akt may not necessary for eNOS binding to Akt 
in vitro (data not shown). However, the detailed interactions among PKCe, Akt and eNOS are still 
under investigation. 
PKC& is a positive regulator for the formation of PKC&-Akt-eNOS Signaling modules. 
Previous studies have focused on the individual roles of PKCe, Akt and eNOS as 
cardioprotective proteins. These studies include one in which cardiac-specific expression of 
constitutively active Akt was found to reduce infarct size and apoptosis after ischemia-reperfusion 
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injury (62). In another investigation, myocardial overexpression of eNOS was found to greatly 
stimulate cardiac nitric oxide production and to protect the heart against ischemia/reperfusion 
injury. Despite this, the effect of PKC€ on the regulation of Akt and eNOS is controversial, and 
data regarding the association of these molecules is particularly lacking in cardiac cells. Amino 
acid sequence analyses reveal that both Akt and eNOS contain multiple potential PKC 
phosphorylation sites. In our study, we found that PKC€ could directly phosphorylate Akt and 
eNOS in vitro, whereas, cardiac-specific overexpression of PKC€ induces increased 
phosphorylation of both Akt and eNOS. 
Previous studies have shown that overexpression of PKCa stimulated the activation of 
Akt. In contrast, several other investigators reported that in A549 and HEK293 cells, the 
phosphatidylinositol 3-kinase/Akt signaling pathway was negatively regulated by PKC (176). 
PMA-induced apoptosis was accompanied by inhibition of Akt activity (149). Similarly, PKC 
activation inhibited eNOS activity by attenuating eNOS phosphorylation on Ser1177 and 
increasing phosphorylation of Thr495 in cardiovascular endothelial cells (123, 124). Thus, it was 
unclear in what manner PKC€, Akt and eNOS might interact to regulate each other in the setting 
of cardioprotection. In the present study, cardiac PKC€ was found to serve as a positive regulator 
of the formation and regulation of PKC€-Akt-eNOS signaling modules in mouse hearts. We found 
that activation of PKC€ enhances the module formation, and the phosphorylation modification 
induced by PKC€ may alter the conformation of both Akt and eNOS and thereby further enhance 
their activity both in vitro and in vivo. These data indicate that through the increased formation of 
PKC€-Akt-eNOS Signaling modules, activation of PKC€ may promote cell survival and stimulate 
nitric oxide synthesis, and therefore contribute to the genesis of cardioprotection against ischemic 
injury. 
Regarding the finding that PKC€ can directly phosphorylate eNOS and increase eNOS 
activity in vitro, the possibility exists that the purity of eNOS recombinant protein may influence 
the in vitro results. Nonetheless, the increased eNOS activity appear to be PKC€-dependent. 
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PKCe is a candidate for PDK2 
Akt has two conserved phosphorylation sites, Thr30S, and Ser473, which are necessary for its 
maximum activation. Generally, the upstream kinase that fulfils the phosphorylation of Thr30S is 
PDK-1. But the upstream kinases that are responsible for the Ser473 phosphorylation is 
unknown, and has been tentatively named "PDK-2". Several candidates have been proposed, 
including PKCs (34 ,190), a lipid-raft-associated kinase (S4), or simply the autophosphorylation 
processes followed by the PDK-1 activity (1). In the present study, we tested the hypothesis that 
PKCE may exhibit PDK-2 activity by phosphorylating Akt Ser473. Interestingly, we found that 
PKCE did indeed phosphorylate Akt Ser473 in vitro, indicating PKCE maybe one of the candidates 
in vivo to target Akt and increase Akt activation by modifying Ser473 phosphorylation. 
Determination of the ability of PKCE to phosphorylate Akt on Ser473 in vivo, and the physiological 
importance of this post-translational modification is an extensive process that is beyond the scope 
of the current investigation. 
In summary, this study successfully characterized myocardial PKCE-Akt-eNOS signaling 
modules, which can serve as a good model for future research addressing the signaling 
mechanisms underlying PKCE-mediated cardioprotection and other phenotypes. The present 
study provided new information about the molecular architecture of PKCE-Akt-eNOS signaling 
modules, the subcellular localization of these modules, and the dynamic modulation of these 
modules during the development of the cardioprotective phenotype. These studies are critical 
steps towards our goal of defining the cardiac proteome, the multiple integrated functional 
subproteomes that compose this proteome, and the specific signaling modules required for 
unique cellular functions. 
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Figure 17. PKCe directly interacts with Akt and eNOS in vitro GST-PKCE fusion 
proteins were incubated with recombinant Akt or eNOS, followed by SDS-PAGE and 
Western blotting for Akt or eNOS. a. GST-PKCE interacts with Akt in vitro, and 
preferentially interacts with recombinant active Akt when compared with recombinant 
inactive Akt; b. GST-PKCE had higher binding affinity with the Akt PH domain when 
compared with PH domain deleted Akt; c. GST-PKCE also physically interacts with 
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Figure 18. Activation of both PKCe and Akt enhanced PKCe-Akt-eNOS module 
formation in vitro. a. Left, recombinant Akt and eNOS were incubated with or without 
PKCe followed by eNOS immunoprecipitation and Akt immunoblotting. Recruitment of 
PKCE increased the binding affinity of eNOS with Akt; right, recombinant PKCE was 
further incubated with Akt and eNOS plus or minus potent PKC activators phorbol ester 
(PMA) and phosphatidylserine (PS) followed by immunoprecipitation of PKCE and blotting 
for Akt or eNOS. PMAlPS-activated PKCE exhibited higher affinity for Akt and eNOS 
compared with that of PKCE without stimulation. b PKCE and eNOS with active or inactive 
Akt recombinant proteins. Activation of Akt also enhanced the interaction of PKCE with 
Akt and eNOS. 
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Figure 19. Formation of PKCe-Akt-eNOS signaling modules in vivo. Mouse hearts 
were homogenized and subjected to gel filtration chromatography using a Sephacryl 
S400 column followed by immunoprecipitation with PKCE antibodies and immunoblotting 
for PKCE, Akt and eNOS. a. The chromatographic profiles of PKCE-associated Akt and 
eNOS protein complexes in the normal mouse hearts; b the chromatographic profiles of 
PKCE-associated Akt and eNOS protein complexes in the PKCE-transgenic mouse 
hearts. Akt and eNOS co-precipitated with PKCE in multiple fractions to form a variety of 
different sized PKCE complexes. Compared with the profiles of non-transgenic mouse 
hearts, the expression profiles of PKCE-Akt-eNOS signaling modules in PKCE-
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Figure 20. PKCE phosphorylates and enhances activation of Akt and eNOS in vitro. 
a. Recombinant Akt or eNOS incubated with recombinant PKCE in the presence of the 
PKC activators phorbol ester (PMA) and phosphatidylserine (PS) and p32_y_ATP. After 
SOS-PAGE separation, phosphorylation was visualized by autoradiography; b. After 
incubating recombinant inactive Akt or eNOS with PKCE, Akt and eNOS activity were 
assessed by its ability to phosphorylate GSK-3~ or produce nitrate/nitrite, respectively. 
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Figure 21. PKCE directly phosphorylated Akt at its Ser473 site in vitro. After 
incubating PKCE with recombinant Akt, Ser473 phosphorylation was detected by site-
specific antibody phospho-Akt-Ser473. Addition of recombinant PKCE significantly 
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Figure 22. Effect of PKCe on the phosphorylation and activation of Akt in 
vivo 
a. Non-transgenic and PKCf: transgenic mouse hearts were homogenized, and 
separated with SDS-PAGE followed by immunoblotting with Akt, PKCE and site-
specific phospho-Akt antibodies. Compared with non-transgenic animals, 
phosphorylation of Akt on its activation sites Thr-308 and Ser-473 was 
significantly increased in cardioprotective PKCE transgenic mice; b. Total Akt 
activity and PKCE-associated Akt activity was measured by its ability to 
phosphorylate GSK-3~. Total cardiac cellular Akt activity was increased in PKCE 
cardioprotected mice when compared with non-transgenic mice. Moreover, 
PKCE-associated Akt activity had greater elevation when compared with the 
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Figure 23. Effect of PKCe on the phosphorylation of eNOS in vivo. Non-transgenic 
and PKCe transgenic mouse hearts were homogenized and separated with SDS-PAGE 
followed by immunoblotting with the eNOS and site-specific phospho-eNOS Ser1177 
antibodies. Compared with non-transgenic animals, phosphorylation of eNOS on serine-
1177, the Akt-specific activation site, was also enhanced in the PKCe transgenic mice. 
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